The Gastrointestinal Exertional Heat Stroke Paradigm: Pathophysiology, Assessment, Severity, Aetiology and Nutritional Countermeasures by Ogden, Henry B. et al.
1 
Title: 1 
The Gastrointestinal Exertional Heat Stroke Paradigm: Pathophysiology, Assessment, 2 
Severity, Aetiology and Nutritional Countermeasures 3 
Authors: 4 
Henry B. Ogden 1, Robert B. Child 2, Joanne L. Fallowfield 3, Simon K. Delves 3 Caroline S. 5 
Westwood 1 and Joseph D. Layden 1 6 
Author Address: 7 
1 Faculty of Sport, Health and Wellbeing, Plymouth MARJON University, United Kingdom 8 
2 School of Chemical Engineering, University of Birmingham, United Kingdom 9 
3 Institute of Naval Medicine, Alverstoke, United Kingdom 10 
Corresponding Author: 11 
Henry B. Ogden 12 
Plymouth MARJON University 13 
Faculty of Sport, Health and Wellbeing,  14 
Derriford Rd, Plymouth, PL6 8BH, United Kingdom 15 
Telephone: 0791 454 0094 16 
Email: ogden.h@pgr.marjon.ac.uk 17 
Conflict of Interest:  18 
All authors declare that there is no conflict of interest regarding the publication of this paper 19 
Key Words:  20 
Exercise, Sport, Nutrition, Supplement, Gut 21 
  22 
2 
Abstract 23 
Exertional heat stroke (EHS) is a life-threatening medical condition involving 24 
thermoregulatory failure and is the most severe condition along a continuum of heat related 25 
illnesses. Current EHS policy guidance principally advocates a thermoregulatory management 26 
approach, despite growing recognition that gastrointestinal (GI) microbial translocation 27 
contributes to the pathophysiology. Contemporary research has focussed on understanding 28 
the relevance of GI barrier integrity and strategies to maintain it during periods of exertional-29 
heat stress. GI barrier integrity can be assessed non-invasively using a variety of in vivo 30 
techniques, including active inert mixed-weight molecular probe recovery tests and passive 31 
biomarkers indicative of GI structural integrity loss or microbial translocation. Strenuous 32 
exercise is well-characterised to disrupt GI barrier integrity, and aspects of this response 33 
correlate with the corresponding magnitude of thermal strain. The aetiology of GI barrier 34 
integrity loss following exertional-heat stress is poorly understood, though may directly relate 35 
to localised hyperthermia, splanchnic hypoperfusion mediated ischemic injury, and 36 
alternations in several neuroendocrine-immune responses. Nutritional countermeasures to 37 
maintain GI barrier integrity following exertional-heat stress provide a promising approach to 38 
mitigate EHS. The focus of this review is to evaluate: (1) the GI paradigm of exertional heat 39 
stroke; (2) techniques to assess GI barrier integrity; (3) typical GI barrier integrity responses to 40 
exertional-heat stress; (4) the aetiology of GI barrier integrity loss following exertional-heat 41 
stress; and (5) nutritional countermeasures to maintain GI barrier integrity in response to 42 
exertional-heat stress. 43 
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Abbreviations 45 
BC  Bovine Colostrum 46 
Caco-2  Human Colonic Carcinoma Cell Line 47 
CFU  Colony Forming Units 48 
CHO  Carbohydrate 49 
CHS  Classic Heat Stroke 50 
DSAT  Dual-Sugar Absorption Test 51 
EHS  Exertional Heat Stroke 52 
GI  Gastrointestinal 53 
I-BABP  Ileal Bile-Acid Binding Protein 54 
I-FABP  Intestinal Fatty Acid Binding Protein 55 
IFN  Interferon 56 
IGF-1  Insulin-Like Growth Factor-1 57 
I-HSP  Intracellular Heat Shock Protein  58 
IL  Interleukin 59 
kDa  Kilodalton  60 
LBP  Lipopolysaccharide Binding Protein 61 
LPS  Lipopolysaccharide 62 
L/R  Lactulose-to-Rhamnose Ratio 63 
MOF  Multiple Organ Failure 64 
MSAT  Multi-Sugar Absorption Test 65 
MT  Microbial Translocation 66 
NO  Nitric Oxide 67 
NO3  Nitrate 68 
NO2  Nitrite 69 
NOS  Nitric Oxide Synthase 70 
NSAIDs Non-Steroidal Anti-Inflammatory Drugs 71 
PAMPs  Pathogen Associated-Molecular Patterns 72 
PCT  Procalcitonin 73 
RDA  Recommended Daily Allowance 74 
RES  Reticuloendothelial system 75 
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RH  Relative Humidity 76 
SAPS  Simplified Acute Physiology Score 77 
sCD14  Soluble Cluster of Differentiation 14 78 
SIRS  Systemic Inflammatory Response Syndrome 79 
S/E  Sucralose-to-Erythritol Ratio 80 
S/R  Sucrose-to-Rhamnose Ratio 81 
Tcore  Core Body Temperature 82 
TJ  Tight Junction 83 
TLR  Toll-Like Receptor 84 
TNF  Tumour Necrosis Factor 85 
VO2max  Maximal Oxygen Uptake 86 
Wattmax Maximal Power (wattage) Output 87 
ZnC  Zinc Carnosine 88 
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Introduction 90 
Exertional heat stroke (EHS) is a life-threatening medical condition involving 91 
thermoregulatory failure, which is the most severe condition along a continuum of heat-92 
related illnesses [1]. Although anecdotal records from biblical times have documented 93 
mortality from EHS [2-3], the condition still has no universal medical definition [4]. Instead, 94 
the most popular definitions broadly outline characteristic patient symptoms at time of clinical 95 
admission [5]. These principally include: (1) a core body temperature (Tcore) above 40°C; (2) 96 
severe central nervous system disturbance (e.g. delirium, seizures, coma); and (3) multiple 97 
organ injury. Whilst classic heat stroke (CHS) primarily impacts incapacitated individuals (e.g. 98 
elderly, infants, chronic illness) whose thermoregulatory responses  are unable to compensate 99 
for increased ambient temperatures [6], EHS sporadically impacts individuals (e.g. athletes, 100 
military personnel, firefighters) engaged in arduous physical activity [7]. Indeed, the primary 101 
cause of EHS is prolonged metabolic heat production, whilst exposure to high ambient 102 
temperature is less important than in CHS cases, despite further compromising 103 
thermoregulation [8]. 104 
The incidence of EHS has been frequently surveyed within high-risk populations since 105 
the beginning of the 20th century [3], though issues surrounding misdiagnosis (e.g. with less 106 
severe heat illness events) has generally limited accurate classification [9-10]. Over the last 107 
two-decades, the annual incidence of EHS has remained relatively stable within both athletic 108 
[11] and military [12] settings. Indeed, prevailing EHS incidence rates are reported to be circa: 109 
0.1-1.5 cases per 10,000 US high school athletes per season [13-14]; 0.5-20 cases per 10,000 110 
entrants during warm weather endurance races [15-17]; and 2-8 cases per 10,000 person 111 
years in both the United Kingdom [18] and United States [12, 19] armed forces. Given global 112 
predications of increased ambient surface temperature, coupled with a greater frequency, 113 
duration and intensity of extreme weather events, the risk of EHS is likely to increase [20]. 114 
Whilst timely medical intervention (e.g. whole-body cooling) can help prevent direct mortality 115 
from EHS [21], many affected individuals still experience long-term health complications 116 
because of residual organ damage. These health-complications include: heat intolerance [22], 117 
neurological impairment [23], chronic kidney disease [24] and cardiovascular disease [25]. The 118 
burden of EHS not only relates to the health of the impacted patients, but can also result in 119 
reduced occupational effectiveness [26-27], significant medical/legal expenses [28-29], and in 120 
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some instances high-profile media criticism [30-31] to the patients governing body or 121 
employer. In consideration of these issues, numerous published consensus documents have 122 
provided occupational guidance on effective management of EHS (e.g. [32-35]). However, 123 
these documents predominately focus on a thermoregulatory approach to disease 124 
management (e.g. cooling, heat acclimation). A gastrointestinal paradigm of EHS 125 
pathophysiology (also known as “endotoxemia” or “heat sepsis”) is starting to receive more 126 
extensive recognition as a secondary pathway for EHS management [36-37], though 127 
consensus documents are present unavaliable.  128 
The gastrointestinal (GI) tract, is an organ extending between the stomach to the 129 
colon. It is the human body’s longest mucosal interface (250-400 m2) forming a selectively 130 
permeable barrier to the external environment. The GI microbiota is a collection of 131 
microorganisms that colonise the GI tract and have co-evolved inside humans to provide 132 
various mutually beneficial functions [38]. The GI microbiota has an estimated size circa 1014 133 
cells, between 1- to 10-fold greater than the total number of cells within the human body [39]. 134 
Alongside a predominant role in the absorption of dietary nutrients, a second vital function of 135 
the GI tract is to prevent the translocation of immunomodulatory GI microbial products (e.g. 136 
endotoxin, flagellin, bacterial DNA) into the systemic circulation [40]. To achieve this role, the 137 
structure of the GI tracts forms a multi-layered physical and immunological barrier. The 138 
physical barrier comprises a monolayer of epithelial cells interconnected by tight junction (TJ) 139 
protein complexes, and is reinforced by a mucosal lining secreted by goblet cells. The 140 
immunological barrier comprises crypt paneth cells within the epithelial monolayer that 141 
secrete antimicrobial proteins, and gut associated lymphoid tissue within the lamina propria 142 
that stimulate multiple effector immune responses. In healthy individuals, the GI tract is 143 
largely effective in preventing GI microbial translocation (MT) into the systemic circulation 144 
[40], though several reports have hypothesised a fundamental role of GI MT within the 145 
pathophysiology of EHS [36-37]. The focus of this review is to evaluate: (1) the GI paradigm of 146 
EHS; (2) GI barrier integrity assessment techniques; (3) typical GI barrier integrity responses 147 
to exertional-heat stress; (4) the aetiology of GI barrier integrity loss; and (5) nutritional 148 
countermeasures to support GI barrier integrity during exertional-heat stress. 149 
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The GI Exertional Heat Stroke Paradigm 151 
The GI EHS paradigm was first introduced as a novel pathophysiology concept in the 152 
early 1990s [41] and was integrated into conventional EHS medical classifications in 2002 [5]. 153 
The broad scientific basis of the GI EHS paradigm centres on the notion that sustained 154 
exertional-heat strain initiates damage to multiple layers of the GI barrier, which consequently 155 
permits GI MT into the systemic circulation. To counter this response, the liver’s 156 
reticuloendothelial system (RES) provides the first line of GI microbial detoxification (e.g. 157 
kupffer cells and hepatocytes) through the portal circulation. However, this confers only a 158 
limited capacity for microbial neuralization before microbial leakage into the systemic 159 
circulation occurs [42]. Alternatively, GI MT might bypass the RES altogether, instead 160 
translocating directly through the mesenteric lymph nodes into the systemic circulation [43]. 161 
In the systemic circulation MT products are neutralized through multiple host-binding 162 
pathways, including: natural antibodies (e.g. immunoglobin G and M), leukocyte granular 163 
proteins (e.g. bactericidal permeability increasing protein, lactoferrin, lysozyme) and high-164 
density lipoproteins [42]. In EHS patients, it appears that microbial detoxification capabilities 165 
might also be reduced, via the combined effects of RES dysfunction at Tcore above 41-42°C [44] 166 
and immune antibody suppression, as demonstrated following strenuous exercise [45]. Failure 167 
of GI microbial detoxification mechanisms permits binding of unique GI pathogen associated-168 
molecular patterns (PAMP) to toll-like receptors (TLR) located on cell surface membranes [46]. 169 
TLR activation initiates a cascade of intracellular events that culminate in the production of 170 
pro-inflammatory cytokines (e.g. interleukin [IL] 1-β, IL-2, IL-6, IL-8, tumour-necrosis factor 171 
[TNF]-α), which are counteregulated by the production of anti-inflammatory cytokines (e.g. 172 
IL-1ra, IL-4, sIL-6r, IL-10, sTNFr). Downstream of this systemic inflammatory response 173 
syndrome (SIRS), a complex interplay of responses can culminate in haemorrhagic shock, 174 
disseminated intravascular coagulation (DIC), multiple organ failure (MOF) and possibly death 175 
[47]. The GI EHS paradigm is considered to be the primary cause of EHS in cases where Tcore 176 
remains below the threshold (~42-44°C) of heat cytotoxicity [48]. A simplified schematic of 177 
the GI EHS paradigm is shown in Figure 1. Interested readers are referred to several detailed 178 
reviews on this topic [1, 36-37]. 179 
 180 
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[Insert Figure 1 Here] 181 
To date, direct pathophysiological investigation into the GI EHS paradigm has been 182 
limited, which is surprising given the substantial morbidity/mortality associated with the 183 
disease. The best available evidence is reliant on animal experimental models of CHS or 184 
opportunistic monitoring of human EHS patients. In a pioneering study, prior antibiotic 185 
administration in a canine CHS model (peak Tcore= ~43.5°C) both suppressed GI microbial stool 186 
concentration and increased survival rate (71% versus 20%), indirectly suggesting the 187 
importance of inhibited GI MT [49]. In a seminal series of studies using a primate CHS model 188 
(peak Tcore= ~43.5°C), plasma endotoxin concentrations were found to increase in parallel with 189 
Tcore (50-52), but prior antibiotic [50-51] or corticosteroid [52] treatment attenuated this 190 
effect. Importantly, 100% of prior- treated animals survived, in comparison with less than 30% 191 
of control animals. However, once hyperthermia was above the intensity to evoke heat 192 
cytotoxicity (peak Tcore= ~44.5°C), mortality rates were 100% irrespective of pharmaceutical 193 
intervention. This suggests that the GI EHS paradigm is probably most relevant in cases when 194 
Tcore remains below ~42-43°C [48]. Several studies have confirmed these findings in similar 195 
rodent CHS models (peak Tcore= ~43.5°C), whereby prior corticosteroid injection inhibited GI 196 
MT and increased survival rate [53-55], whilst indomethacin injection enhanced gross 197 
morphological GI haemorrhage and suppressed survival rate [56]. 198 
Direct endotoxin injection into rodents before sub-lethal CHS (peak Tcore = ~42-43°C) 199 
unexpected killed 40% of animals (versus 0% in controls; [57]) and/or increased multiple-200 
organ injury [58]. In the only animal models of EHS (peak Tcore= 40.5-42.5°C), significant 201 
histopathological damage to all GI segments [59], in addition to GI epithelial injury [59-60] and 202 
systemic inflammation [61], were observed. However, in comparison to CHS models with a 203 
similar clinical endpoint (peak Tcore= ~42-42.5°C), the magnitude of GI barrier integrity loss was 204 
reduced during EHS, though this was likely attributable to a ~50% lower thermal area [60]. No 205 
published animal EHS research has yet evaluated the role of GI MT on EHS pathophysiology. 206 
However, recent data show the pattern of cytokine response during EHS is largely inconsistent 207 
with typical GI microbial PAMP recognition (e.g. minimal TNF-α/IL-1β response; [60]. With this 208 
is mind, it is plausible intracellular cytokine production initiated following multiple organ 209 
injury (e.g. skeletal muscle; [61]) performs a greater role in EHS pathophysiology than 210 
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previously proposed in GI EHS consensus documents [37, 47].  211 
In humans, the role of GI barrier integrity in the pathophysiology of EHS is a relatively 212 
recent area of research; which has been established on historical evidence of severe GI 213 
symptoms, ulceration and haemorrhage in military EHS fatalities [62-64]. Evidence supporting 214 
the present GI EHS model was first reported by Graber et al. [65], who observed endotoxin 215 
translocation into the systemic circulation and symptomology of experimental endotoxin 216 
shock in a single EHS case report. More substantial evidence was collated in the 1990s, from 217 
EHS patients (peak Tcore = ~42°C) who had been on religious pilgrimage to Mecca [66]. The 218 
plasma endotoxin concentration increased ~1000-fold more than in healthy controls (8.6 219 
ng·ml-1 vs 9 pg·ml-1). In this study, weak correlations were reported between endotoxin and 220 
SIRS responses (e.g. TNF-α r= 0.46; IL-1β r= 0.47), whilst in a follow-up study that did not 221 
monitor endotoxin responses, IL-6 concentration weakly correlated (r= 0.52) with the disease 222 
Simplified Acute Physiology Score (SAPS; [67]). In support, IL-2 (r= 0.56), IL-6 (r= 0.57) and IFN-223 
γ (r= 0.63) concentrations weakly correlated with the SAPS in a cohort of military EHS (peak 224 
Tcore = ~41.5°C) patients, though the SAPS did not correlate with the time-course of any other 225 
cytokine monitored (IL-1β, IL-2ra IL-4, IL-8, IL-10; TNF-α) [68]. Likewise, IL-6 and sTNFR, but 226 
not IL-1ra and C reactive protein, predicted survival in a later cohort of EHS patients (peak Tcore 227 
= ~41.5°C) on Mecca pilgrimage [69]. Whilst none of these studies directly monitored GI MT 228 
responses, sub-clinical exertional-heat stress (Tcore = < 40°C) experiments have reported 229 
similar patterns of endotoxin translocation and SIRS kinetics in some [70-71], but not all cases 230 
[72-73]. 231 
A key limitation of previous research has been the exclusive reliance of endotoxin to 232 
assess GI MT. There is evidence blood samples may be cross-contaminated during collection 233 
or analysis, for example one EHS case study reported the presence of β-glucan (a fungal cell 234 
wall component) in blood which was unlikely to be of GI origin [74]. Variations in sample 235 
contamination might explain EHS induced endotoxemia independent of GI MT [74]. Future 236 
research should focus on determining the sensitivity/specificity of GI barrier/MT biomarkers 237 
on EHS outcome. One potentially relevant novel biomarker is procalcitonin (PCT), a pro-238 
inflammatory acute phase reactant, which offers strong sensitivity/specificity in diagnosing 239 
acute bacterial infections [75]. In EHS patients, PCT measured 2 hours following intensive care 240 
10 
unit admission was able to predict Acute Physiology and Chronic Health Evaluation (APACHE) 241 
II score (r = 0.59) and had an odds-ratio of 2.98 for predicting disease mortality [76]. 242 
Furthermore, in CHS patients, PCT concentrations were significantly greater in fatal versus 243 
non-fatal cases [77-78].  244 
Assessment of GI Barrier Integrity 245 
Various techniques are available for the in vivo assessment of GI barrier integrity. 246 
These techniques can be broadly categorised as either: (1) active tests involving the oral 247 
ingestion and extracellular recovery of water-soluble non-metabolizable inert molecular 248 
probes; (2) passive tests involving monitoring blood biomarkers indicative of GI barrier 249 
integrity; and (3) microbial translocation (MT) tests involving monitoring blood biomarkers 250 
indicative of the passage of GI microbial products across the GI barrier secondary to integrity 251 
loss (Table 1 [40]).  252 
 253 
[Insert Table 1 Here] 254 
 255 
The Dual Sugar Absorption Test (DSAT) is presently promoted as the gold-standard 256 
active GI function test [79], which has received almost exclusive application with the field of 257 
exercise science [80-82]. This test involves co-ingestion of both a large disaccharide (e.g. 258 
lactulose [342 kDa] or cellobiose [342 kDa] ~5 grams) that only transverses the GI tract 259 
paracellularly upon barrier integrity loss, and a small monosaccharide (L-rhamnose [164 kDa] 260 
or D-mannitol [182 kDa] ~1-2 grams) that freely transverses the GI tract transcellularly 261 
independent of barrier integrity [83]. In the five hour period post-ingestion the excretion of 262 
both sugars are measured in urine and are believed to be equally affected by non-mucosal 263 
factors, such as gastric emptying and renal clearance [84]. The urinary ratio of lactulose-to-264 
rhamnose (L/R) relative to the ingested dose is the clinical endpoint of this test. Recently, the 265 
DSAT has been validated in serum/plasma with improved sensitivity over a time-courses 266 
ranging between 60-150 minutes [85-88], and with comparable reliability to traditional 267 
urinary assessment [89]. Unfortunately, the DSAT has several practical limitations, most 268 
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notably: a requirement to perform basal/exercise tests on separate days and a lack of 269 
universal test standardisation (e.g. pre-trial controls, sugar dose, ingestion timing, biofluid 270 
timing) [84]. Furthermore, based on the degradation of lactulose in the large intestine, the 271 
test only provides information regarding small GI barrier function, with further sugar probes 272 
(i.e. multi-sugar absorption test; MSAT) required to assess gastroduodenal (e.g. 273 
sucrose/rhamnose; S/R) and large intestinal (e.g. sucralose/erythritol; S/E) barrier function 274 
[82]. Whilst routine implementation of the MSAT would be desirable, hyperosmolar stress 275 
utilising recommended sugar dosages will cofound the test result. In attempt to overcome this 276 
issue, validation of a low dose (1 gram lactulose, sucrose, sucralose; 0.5 grams L-rhamnose, 277 
erythritol) MSAT protocol has recently been favourable evaluated against the traditional dose 278 
(5 grams lactulose, 2 grams L-rhamnose) DSAT protocol [87,90]. Polyethylene glycols (PEG; 279 
100-4000 kDa) are a less-common, though a validated alternative to the MSAT for whole-GI 280 
barrier integrity assessment [91]. An advantage of PEG assessment is the ability to provide 281 
information on the size based permeability of molecules able to transverse the GI barrier. 282 
However, this method does require additional lifestyle controls, as PEGs can be found in 283 
various commercial/dietary products (e.g. toothpaste, soft drinks) [82]. The application of 284 
single molecular probes tests (e.g. non-metabolizable sugars, 51Cr-EDTA, Iohexol, Blue #1 Dye) 285 
cannot be recommended in exercise-settings given the confounding influence of non-mucosal 286 
factors [84].  287 
Several passive blood-based biomarkers of GI barrier integrity are available, which can 288 
assess epithelial injury to specific regions of GI tract, TJ breakdown and MT [40]. Epithelial 289 
injury to the duodenum and jejunum can be evaluated via intestinal fatty-acid binding protein 290 
(I-FABP); and to the ilium via ileal bile-acid binding protein (I-BABP). These cytosolic proteins 291 
are involved in lipid metabolism, though offer strong diagnostic specificity/sensitivity in 292 
detecting GI barrier integrity loss [92], given their tissue specificity and transient 11 minute 293 
half-life [93]. Alternative biomarkers of GI epithelial/transmural injury include: alpha-294 
glutathione s-transferase (α-GST), diamine oxidase (DAO) and smooth muscle protein 22 295 
(SM22); however a lack of tissue specificity limits their application in settings (e.g. exercise) 296 
where multiple-organ injury is commonplace [40, 94]. There is presently no available 297 
biomarker of large intestinal epithelial injury. To assess TJ breakdown, zonulin, a pre-curser 298 
protein to haptoglobin, has received most widespread attention, given its recognised role in 299 
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disassembling GI TJs [95]. However, the two commercial assays presently available for this 300 
biomarker are susceptible to cross-reactivity (e.g. for complement protein C3). Consequently 301 
data collected with this technique should be interpreted with caution until the methods have 302 
been validated [96]. Claudin-3, is a non-tissue specific, highly expressed GI TJ protein, which is 303 
an emerging biomarker for TJ breakdown. Preliminary data has shown claudin-3 304 
concentrations are elevated in clinical conditions where GI TJ damage has been confirmed 305 
histologically [97]. The test-retest reliability of I-FABP and claudin-3 was recently considered 306 
acceptable when assessed both at rest and following exertional-heat stress [89]. All GI 307 
epithelial injury/TJ breakdown biomarkers can be assayed in plasma/serum by ELISA, whilst 308 
future developments in auto-analysers and validation of capillary blood and urine samples 309 
have potential to make assessment simpler in the future.   310 
The definition of MT was traditionally founded on the transloaction of live bacteria 311 
from the GI lumen into the mesenteric lymph. However, given practical constraints of 312 
mesenteric lymph biopsy in healthy humans, this definition has been extended to include the 313 
detection of microbial products/fragments in blood [98]. To determine GI MT, measurement 314 
of endotoxin, a form of lipopolysaccharide (LPS) located on the outer membrane of gram-315 
negative bacteria, has been widespread [80]. Endotoxin is detectable within the 316 
portal/systemic circulations following bacterial cleavage during both cell lysis and division, 317 
with assessment widely undertaken using the chromogenic limulus amoebocyte lysate (LAL) 318 
assay. Whilst popular, there are major flaws to endotoxin assessment, as it is prone to false-319 
positive (e.g. from exogenous contamination, cross-reactivity) and false-negative (e.g. from 320 
hepatic clearance, immune neutralization) results [99]. Two indirect surrogate biomarkers for 321 
endotoxin exposure that can be quantified by ELISA are the acute phase proteins: 322 
lipopolysaccharide binding-protein (LBP; [100]) and soluble-CD14 (sCD14-ST; [100]). Whilst 323 
the roles of these biomarkers have been characterised during life-threatening septic shock 324 
[101], evidence regarding their time-course, sensitivity and specificity in predicting transient 325 
GI MT following exertional-heat stress is sparse [80]. D-lactate is a secondary enantiomer of 326 
L-lactate, hypothesised as a biomarker of GI MT given that the enzyme D-lactate 327 
dehydrogenase is specific to bacteria [102]. That said, human cells do produce small-quantities 328 
of D-lactate through secondary methylglyoxal metabolism [102]. Whilst D-lactate has been 329 
shown to predict GI MT in animal models of gut trauma [103-104], its low-molecular weight 330 
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(0.09 kDa) might permit false-positive results through transcellular translocation following 331 
production within the GI tract. Bacterial DNA (bactDNA) is a stable bacterial component, which 332 
through targeting phyla with high GI specificity offers potential as an improved MT biomarker 333 
[105]. Whilst a universal analytical procedure is currently lacking (e.g. target primers, 334 
positive/negative controls), one major advantage of bactDNA over endotoxin assessment, is 335 
an apparent lack of rapid hepatic clearance [46]. As the GI microbiota is dominated (≥ 90%) by 336 
two bacterial phlya Firmicutes and Bacteroidetes, which comprise only a minor proportion (0-337 
10%) of the whole blood/plasma microbiota [106], developing methodologies that target 338 
these specific gene regions are likely to provide high GI specificity. Pioneering studies have 339 
shown total 16S DNA to offer good reliability at rest and post exertional-heat stress, however 340 
Bacteroides DNA (the dominant Bacteroidetes bacterial genus) offered poor reliability at both 341 
time points [89].  342 
Severity of GI Barrier Integrity loss following Exertional-Heat Stress 343 
Numerous research models have characterised the influence of exertional-heat stress 344 
on GI barrier integrity. This research has primarily monitored small intestinal integrity using 345 
the DSAT, though attempts have been made to quantify gastroduodenal and large intestinal 346 
integrity using the MSAT [80]. Over the last decade, several passive GI integrity and/or MT 347 
biomarkers have become commonplace as an alternative to, or for use in combination with 348 
the DSAT. Generally, I-FABP has been monitored to assess GI epithelial integrity, and 349 
endotoxin to assess GI MT. The exercise models assessed are disparate, ranging from 45 350 
minutes brisk walking [107] to a 230-km ultramarathon [71]. That said, most studies comprise 351 
1-2 hours of continuous, submaximal (60-70% VO2max) running or cycling. Given the 352 
hypothesised relevance of GI barrier integrity within the pathophysiology of EHS, the impact 353 
of exercise-induced thermal strain (e.g. Tcore) on GI barrier integrity has been a specific topic 354 
of investigation [81]. In comparison to acute exercise-interventions, few studies have 355 
attempted to evaluate the effect of either chronic exercise training or multi-day occupational 356 
performance (e.g. sports competition, military/firefightining operation) on GI barrier integrity. 357 
Such exercise models would appear particualaly relevant to EHS incidence, given that many 358 
documented EHS risk factors (e.g. prior heat exposure, skeletal muscle injury) relate to multi-359 
day exercise [37]. Review tables are provided to summarise the effects of acute exercise on: 360 
DSAT (Table 2); I-FABP (Table 3); and MT (Table 4). 361 
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Seminal research using the DSAT, investigated the effects of one hour’s treadmill 362 
running in temperate conditions on GI barrier integrity [108]. These authors found  the DSAT 363 
ratio increased relative to both the magnitude of metabolic (60, 80 and 100% VO2max) and 364 
thermal (38.0, 38.7 and 39.6°C Tcore peak) strain [108]. Later studies monitoring GI barrier 365 
integrity following exercise in temperate conditions corroborated this seminal finding, with 366 
low-to-moderate intensity (~40-60% VO2max) exercise having little influence on DSAT results 367 
compared with rest [e.g. 109-111]; whereas moderate-to-high intensity (~70-120% VO2max) 368 
exercise of durations ≥20 minutes increase permeability by 100-250% [e.g. 86, 88, 112-116]. 369 
Unfortunately, the present data does not allow more specific conclusions to be drawn, given 370 
large intra-study variability in absolute DSAT ratios, which can be attributed to modifications 371 
in the DSAT procedure (e.g. sugar probe type/dose/timing, analytical protocol) and/or a 372 
frequent lack of basal GI permeability correction (Table 2). That said, individual studies 373 
highlight the importance of particular aspects of the exercise stimulus on GI barrier integrity, 374 
with increased DSAT ratios after matched interventions comparing: running and cycling [117]; 375 
permissive dehydration versus rehydration [118-119]; and following ingestion of non-steroidal 376 
anti-inflammatory drugs (NSAID) [120-124]. To date, only two published studies have directly 377 
compared the influence of ambient temperature on GI barrier permeability [115, 125]. In 378 
conflict with a priori hypotheses, the first of these studies found two hours of moderate 379 
intensity (60% VO2max) treadmill running in temperate (22°C/44% relative humidity [RH]) 380 
versus mild hyperthermic (30°C/35% RH) conditions resulted in comparable DSAT responses 381 
(0.025 ± 0.010 vs. 0.026 ± 0.008 [125]). However, these results were perhaps not entirely 382 
surprising given that Tcore responses showed minimal divergence between the two 383 
environmental conditions (e.g. peak Tcore = 38.1°C vs. 38.4°C [125]). A follow-up trial on the 384 
same subjects compared the results of the temperate exercise condition (22°C/44% RH) with 385 
a third trial conduced in a more severe hyperthermic (35°C/26% RH) environment [115]. The 386 
DSAT data (0.032 ± 0.010) remained statistically indifferent to the temperate condition, 387 
despite greater Tcore elevations (e.g. peak Tcore = 39.6°C [115]). These null findings might be 388 
interpreted with caution, as there was poor analytical reproducibility of sugar concentrations 389 
(duplicate sample coefficient of variation = 13.8%) and no basal DSAT correction.  390 
In comparison with the extensive literature examining the acute effect of exercise on 391 
small GI integrity using the DSAT, few studies have assessed the influence of exercise or 392 
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exertional-heat stress on either gastroduodenal or large GI barrier integrity utilising the MSAT 393 
[80]. In the only published evidence where the MSAT was applied with reference probe co-394 
administration [82], both gastroduodenal (S/R; [124]) and large intestinal (S/E; [86]) integrity 395 
were unaltered following one hour of moderate intensity cycling (70% wattmax) in temperate 396 
conditions (~22°C), which was sufficiently intense to induce detectable small intestinal barrier 397 
integrity loss using the DSAT. Similarly, gastroduodenal integrity, measured using a single 398 
sugar-probe (sucrose) has been shown to be unaltered following one hour of moderate 399 
intensity treadmill running (40-80% VO2max) in temperate conditions [108, 119, 122], 18 400 
repeated 400 metre supramaximal track sprints (120% VO2max) in temperate conditions [88] 401 
and a ~33 minute exercise capacity trial at 80% ventilatory threshold in the heat (35°C/40% 402 
RH [126]). No further studies have measured large intestinal integrity following acute exercise 403 
using a single sugar-probe (sucralose). There is a clear gap in the literature regarding the 404 
influence of exertional-heat stress on large intestinal integrity, which warrants future 405 
investigation given the greater microbiota concentration in this segment of the GI tract (e.g. 406 
duodenum = <103, ilium 103-107, colon= 1012- 1014) [166].   407 
 408 
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 410 
Application of I-FABP as a biomarker of small-intestinal (duodenal and jejeneal) 411 
epithelial injury was first applied in exercise settings during a series of studies conducted in 412 
the Netherlands, which demonstrated peak concentrations (~50-100% increase) immediately 413 
following termination of a one-hour moderate-intensity (70% Wattmax) cycle [86, 124, 127]. I-414 
FABP responses showed weak correlations with I-BABP (i.e. ilieum injury) and the DSAT [86], 415 
suggestive of inconsistant injury across the small intestine. Since then, low intensity exercise 416 
(~50% VO2max) in temperate environments has typically shown little effect on I-FABP 417 
concentrations [128-130], but moderate-to-high intensity exercise (60-120% VO2max) elevates 418 
concentrations by 50-250% [88, 125, 131-133]. Where measured, I-FABP responses quickly 419 
recover within 1-2 hours of exercise termination, irrespective of the intensity/duration of the 420 
protocol [125, 131]. Like DSAT results, I-FABP responses are elevated in otherwise matched 421 
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exercise-interventions comparing:  hypoxic (FiO2 = 0.14) versus normoxic environments [128, 422 
134]; permissive dehydration versus rehydration [135]; and post NSAID ingestion [124]. In 423 
comparison, since initial investigation [86], no studies have monitored the magnitude and 424 
time-course of I-BABP responses following exericse. Several studies have attempted to 425 
elucidate the influence of ambient temperature on GI epithelial injury [115, 125, 133, 136-426 
137]. Compared with modest increases in I-FABP (127%) following two hours of moderate 427 
intensity cycling (60% VO2max) in temperate (22°C/44% RH) conditions (peak Tcore 38.1°C), 428 
performance of matched exercise in both mild (30°C/35% RH [115]) and severe heat stress 429 
conditions (35°C/26% RH; [125]) vastly enhanced peak Tcore (38.4°C and 39.6°C) and 430 
percentage change in I-FABP (184% and 432%) responses, respectively. Furthermore, a 431 
moderate correlation (r = 0.63) was shown between peak Tcore and I-FABP concentration in 432 
these studies. Ingestion of cold (7°C) relative to temperate (22°C) water during two hours 433 
moderate intensity cycling (60% VO2max) in the heat, blunted the rise in both Tcore (38.4 vs 434 
38.8°C) and I-FABP (~400% vs 500%) concentration [137], though whether these responses 435 
are directly related is questionable. These conclusions were recently substantiated following 436 
one hour of low intensity (50-70% wattmax) cycling, where I-FABP concentration increased 437 
following performance in a hot (35°C/53 % RH; 140%), but not temperate (20°C/55% RH; 29%) 438 
ambient environment [133].  Importantly, these observations have been directly attributed to 439 
the influence of ambient temperature on whole-body thermal strain, given that when relative 440 
exercise-intensity is matched (VO2max, Tcore, heart rate), the influence of ambient heat stress 441 
(20 vs. 30C°) on I-FABP responses is abolished [136]. One study reported GI TJ breakdown 442 
(claudin-3) to increase to a similar extent following one hour of running in a temperate 443 
(22°C/62% RH) versus hot (33°C/50% RH) ambient environment [138], suggestive that TJ 444 
breakdown is insensitive to thermal stress. Alternatively, I-FABP and claudin-3 responses 445 
positively correlated (r = 0.41) following an 80-minute brisk walk (6 km·h-1/7% incline) in the 446 
heat (35°C/30% RH) [89].  447 
 448 
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Endotoxin is a traditionally popular biomarker of GI MT and was the first technique 451 
utilised to assess GI barrier integrity in exercise settings. Seminal research monitoring 452 
endotoxin concentrations following exercise, found concentrations to increase transiently to 453 
magnitudes comparable to clinical sepsis patients (~50-500 pg·ml-1) when measured following 454 
competitive ultra-endurance events [80]. These included: an ultra-triathlon [139], a 90 km 455 
ultra-marathon [140], a 100-mile cycle race [141] and a 42.2 km marathon [142]. More 456 
recently, only minor increases in endotoxin concentrations have been shown following 457 
comparable duration competitive ultra-endurance races [71, 144-145], whilst moderate 458 
intensity exercise (≤2 hours; 50-70% VO2max) performed in a temperate environment generally 459 
does not influence circulating endotoxin concentrations [132-133, 138, 143]. These discrepant 460 
results may be due to cross-contamination from β-glucan during early research, which 461 
following development of more robust endotoxin assays is now less of an issue [144]. It 462 
appears a presently undefined threshold of GI barrier integrity loss is required to induce 463 
endotoxemia following exercise, given that endotoxin concentrations are often unchanged 464 
from rest irrespective despite concurrent rises in DSAT or I-FABP concentrations [116, 125, 465 
132]. When endotoxin is assessed from systemic blood samples, hepatic/immune 466 
detoxification might lead to false-negative results, and in exercise settings access to portal 467 
blood is rarely feasible. Given the large range in absolute endotoxin concentrations reported 468 
between studies (Table 4), several recent attempts have been made to measure MT with 469 
alternative biomarkers, though results are equally inconsistent [131, 146-148]. Thermal stress 470 
appears to enhance endotoxin translocation above matched exercise performed in temperate 471 
conditions. In an early study, endotoxin concentrations increased linearly above 38.5°C when 472 
(measured at 0.5°C Tcore increments), during uncompensable (40°C/30% RH) treadmill walking 473 
(4 km·h-1) [146]. Likewise, a follow-up study found one hour of moderate intensity treadmill 474 
running (70% VO2max) only increased endotoxin concentrations in hot (33°C/50% RH; 54%), but 475 
not temperate (22°C/62% RH) conditions [138]. In a series of studies monitoring endotoxin 476 
concentrations following two hours moderate intensity treadmill running (60% VO2max), 477 
concentrations were found to increase by 4-10 pg·ml-1 irrespective of the thermal 478 
environment (22-35°C; [115, 125, 149]. Numerous other studies have measured endotoxin 479 
concentrations following exertional-heat stress, though large intra-study variability in 480 
absolute concentration make it impossible to make precise recommendations regarding the 481 
typical magnitude of response (Table 4). In studies where endotoxin concentrations do 482 
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increase following exertional-heat stress, responses peak immediately upon trial termination 483 
[138, 150].  484 
[Insert Table 4 Here] 485 
Whilst many studies have monitored GI barrier integrity responses following acute 486 
exertional-heat stress, relatively few studies have monitored GI barrier integrity following 487 
chronic (multi-day) exertional-heat stress. Where chronic exercise studies have been 488 
undertaken, they predominately focus on the influence of structured heat acclimation on GI 489 
barrier integrity. In an early study, involving seven days fixed-intensity heat acclimation (100 490 
minutes walking at 6.3 km·h-1 in 46.5°C/20% RH), endotoxin concentrations remained stable 491 
both at rest and following exertional-heat stress, despite Tcore peak above 39.0°C [143]. 492 
Utilising a variation of this experimental design, five consecutive days treadmill running at 493 
lactate threshold pace in the heat (40°C/40% RH) until Tcore had risen 2°C above rest, evoked 494 
comparable post-exericse I-FABP and endotoxin responses compared to day-one [72]. 495 
Likewise, 10 days of fixed-intensity heat acclimation (one hour running at 50% VO2max in 496 
40°C/25% RH), had no influence on post-exericse I-FABP concentration compared to day one 497 
[128]. In a recent study, neither seven nor thirteen days isothermic heat-acclimation (90 498 
minutes to sustain Tcore ~38.5°C) blunted the rise in endotoxin concentration following 45 499 
minutes low intensity (40% wattmax) cycling in the heat (40°C/ 50% RH), despite large 500 
reductions in thermal strain [151]. In a non-heat acclimation study, 14 days of 20% increased 501 
training versus standard load, led to a reduction in resting endotoxin concentration (35%), but 502 
did not influence peak concentrations following a 70% VO2max treadmill run (35°C/40% RH) 503 
until a Tcore of 39.5°C was attained [150]. The influence of aerobic fitness has been shown to 504 
both increase (I-FABP; [152]) and reduce (endotoxin; [146]) GI barrier integrity loss following 505 
exertional heat stress that evoked comprable thermal strain between groups. Future research, 506 
using well-designed and adequately powered studies coupled with sensitive biomarkers, is 507 
required to determine the influence of heat acclimation on GI barrier integrity. As well as 508 
ensuring an appropriate sample size, an exertional-heat stress protocol that evokes high 509 
physiological strain should be used, using study participants that posse the same physiological 510 
characteristics as the target population. 511 
 512 
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Aetiology of GI Barrier Integrity Loss following Exertional-Heat Stress 513 
The aetiology of exertional-heat stroke induced GI barrier loss appears multifactorial 514 
and is incompletely understood. The best supported explanations relate to: hyperthermia-515 
mediated dysregulation of GI TJs [153]; splanchnic hypoperfusion-mediated ischemia-516 
reperfusion injury [82, 155]; and alternations in several complex neuroendocrine-immune 517 
related interactions [156]. 518 
Increased tissue metabolic rate during strenuous exercise, and/or environmental heat 519 
stress, can evoke uncompensable heat strain on the body as thermoregulatory cooling 520 
responses (e.g. sweating and increased skin perfusion) become overwhelmed [157]. Within 521 
the GI tract, exertional-heat stress results in a relatively uniform rise in tissue temperature 522 
across both the small and large intestinal segments (though this rise is lower in the stomach), 523 
which can be predicted from Tcore assessement in the distal colon [158]. This will weaken the 524 
GI barrier by morphologically disrupting the enterocyte structure and opening TJ complexes 525 
[153]. Cell culture models have consistently shown temperature elevations from 1.3°C to 526 
rapidly disrupt the GI barrier in a dose/duration dependant manner [159]. Rodent studies 527 
support these conclusions, with evidence of both histopathological GI damage and increased 528 
GI permeability following passive heating >40°C [154]. Nevertheless, the mechanistic 529 
pathways directly linking hyperthermia to GI barrier integrity loss have been poorly 530 
characterised. The available evidence suggests that heat stress positively regulates the GI 531 
barrier through sodium-dependant glucose cotransporter/tyrosine kinase pathways [160] and 532 
negatively through the myosin light-chain kinase/protein kinase-c pathways [161]. Ethical 533 
constraints have prevented laboratory GI barrier integrity assessment following severe 534 
hyperthermia (>40°C) in humans. However, a systematic review including available data up 535 
until September 2016 reported strong correlations (r= 0.79) between peak Tcore and GI barrier 536 
integrity loss (5-hr urine DSAT only) when all available Tcore assessment techniques were 537 
included [81]. Data presented in tables 2-4 show a weak correlation between peak post-538 
exercise Tcore (rectal, gastrointestinal or oesophageal) with peak I-FABP (Δ; r= 0.52; p = <0.001), 539 
but not the DSAT (5-hr urine only; r= 0.30; p= 0.19), or endotoxin (Δ; r= 0.14; p= 0.56) 540 
concentration (note: studies without Tcore assessment were excluded).  541 
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Splanchnic vascular beds receive ~20% of total resting cardiac output but consume 542 
only 10-20% of the available oxygen [162]. Consequently, blood flow during strenuous 543 
exercise can be safely redistributed from splanchnic organs to skeletal muscle to maintain 544 
aerobic metabolism, and to skin to assist thermoregulation [157]. Hypoperfusion of splanchnic 545 
vascular beds, measured using doppler ultrasonography, appears to be proportional to 546 
exercise intensity and duration [162]. Specifically, splanchnic blood flow declines by 30-60% 547 
following both 30 minutes of moderate-intensity (60-70% VO2max) and 1-2 hours of low-548 
intensity exercise (40-50% VO2max) [163]. These responses appear amplified when exercise is 549 
performed in a warm environment [164]. A key downstream event following GI hypoperfusion 550 
is GI ischemia measured using gastric tonometry, which is also known to be suppressed 551 
following exercise in an intensity dependant manner [86, 165]. Localised GI hypoperfusion is 552 
considered to evoke secondary adenosine triphosphate depletion, acidosis, altered 553 
membrane ion pump activity and oxidative stress, all physiological responses that damage the 554 
GI barrier [154, 159, 167]. One limitation of this research is the inability of tonometry to 555 
measure large intestinal ischemia in exercising humans, especially as the largest microbial 556 
biomass is located in the distal GI segments [166]. The partial pressure of oxygen across the 557 
GI tract displays a proximal-to-distance gradient [168], which might have clinical 558 
manifestations on MT given that the integrity of the large intestine is considered less 559 
susceptible to ischemic injury [82]. Contrary to previous beliefs, the influence of splanchnic 560 
reperfusion following exertional-heat stress appears to be an unlikely mechanism of GI barrier 561 
integrity loss [82]. Indeed, one study found plasma I-FABP concentrations correlated with 562 
splanchnic (stomach) hypoperfusion during moderate intensity exercise (r= 0.59), though 563 
following post-exercise intestinal reperfusion, I-FABP concentrations began to recover within 564 
the first 10 minutes [86]. 565 
Inflammatory cytokines comprise a large family of intercellular pleiotropic signalling 566 
molecules that perform many regulatory functions, and are primarily involved in innate 567 
immunity [169]. Strenuous exercise induces strong pro-inflammatory (TNF-α, IL-1β, IL-6, IFN-568 
γ), followed by anti-inflammatory (IL-1ra, IL-4, IL-10) responses throughout numerous cells 569 
and tissues across the body [170]. The specific biological roles of individual cytokines are 570 
incompletely understood and are likely context dependant. That said, several pro-571 
inflammatory cytokines released post-exercise (e.g. TNF-α) appear to disrupt GI barrier 572 
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integrity [153]. Potential regulatory mechanisms might include: direct modulation of several 573 
cell signalling pathways that regulate TJ protein complex stability [171-173]; and the indirect 574 
pyrogenic modulation of body temperature where local hyperthermia damages the GI barrier 575 
[174-175]. With EHS cases, pro-inflammatory cytokines are produced upon immune activation 576 
(e.g. nuclear factor kappa-β transcription) following binding between MT products and toll-577 
like receptors located on cell surface membranes [156]. This response appears to operate 578 
through a positive feedback loop that may further promote GI MT, cytokine production, and 579 
potentially culminate in fatal septic shock [176]. 580 
 581 
Nutritional Countermeasures 582 
Nutritional countermeasures could modulate key cellular pathways involved in 583 
mitigating exertional-heat stress induced GI barrier integrity loss. Diet regimens and nutrition 584 
supplements with evidence they can influence GI barrier integrity following exercise and/or 585 
exertional-heat stress will be reviewed. The mechanistic basis of each nutritional intervention, 586 
evidence of improved GI barrier function following exercise and practical recommendations 587 
are presented. 588 
Carbohydrate 589 
Carbohydrates (CHO) are the main macronutrient of western diets and are an essential 590 
energy substrate in susustained moderate and high intensity exercise. The physiological 591 
response to CHO ingestion is highly dependant upon its biochemical formula, where high 592 
glycaemic index CHO (e.g. glucose, maltose) have rapid bioavailability, and low glycaemic 593 
index CHO (e.g. fructose, galactose) have delayed bioavailability. The volume, tonicity and 594 
osmolality of CHO is equally influential. In healthy resting humans, ingestion of a single CHO-595 
rich meal (55-70% of total kilo-calories) evokes equivocal (endotoxin [177-179] or slightly 596 
improved (I-FABP; [180-181]) GI barrier integrity postprandially. However, rodent 597 
experimental models of acute GI distress indicate that oral ingestion of maltodextrin [182] or 598 
sucrose [183] favourably influence GI barrier integrity. Mechanisms of action at the whole-599 
body level are likely multifactorial, including regulation of the GI microbiota [184] and an 600 
elevation of splanchnic perfusion [185]. Nevertheless, in vivo and in vitro studies indicate that 601 
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high glucose exposure might reduce GI TJ stability through an abnormal redistribution of 602 
several TJ proteins [186]. Compared with ingestion of a single CHO-rich meal, ingestion of a 603 
single fat-rich meal results in acute GI MT [178-179, 187].  604 
The ingestion of CHO pre-, during and post-exercise in athletic populations is widely 605 
recommended to improve exercise performance [188], accelerate recovery [189] and 606 
maintain immune function [190]. In comparison, the influence of CHO on GI barrier integrity 607 
has received less attention, despite being associated with the onset of GI complaints [191] and 608 
increased splanchnic perfusion [192]. Contrary to proposed hypotheses, preliminary research 609 
found no influence of CHO beverage ingestion (30-60 g·hour-1 glucose), compared with water, 610 
on GI barrier integrity (utilising the DSAT) during 60-90 minutes of moderate intensity exercise 611 
(70% VO2max) [111, 122]. However, follow-up studies reported attenuated GI barrier integrity 612 
loss (I-FABP and DSAT) with glucose ingestion (60 g·hour-1) during two-hours moderate 613 
intensity running (60% VO2max) in the heat (35°C and 25% relative humidity (RH); [193]), and 614 
with sucrose ingestion (40 g·hour-1) prior/during a one-hour moderate intensity cycle (70% 615 
wattmax) [131]. However, neither intervention ameliorated the severity of GI MT. Formulations 616 
of single- and multi-transportable CHO mixtures (i.e. 1.8 g·min-1 glucose; 1.2 and 0.6 g·min-1 617 
glucose plus fructose; 0.6 and 1.2 g·min-1 glucose plus sucrose) all tended to (interaction effect 618 
p = 0.10) reduce I-FABP concentrations (area under the curve at 30 minute intervals) to a 619 
similar extent relative to water during three hours of low-intensity cycling (50% Wattmax) [130]. 620 
Similarly, ingestion of 60 g·hour-1 of either potato flesh puree or carbohydrate gel (2:1 621 
maltodextrin/fructose) were able to completely attenuate the rise in I-FABP observed 622 
throughout a 2.5 hour mixed-intensity cycle (2 hours 60% VO2max then a 20 km time trial in 623 
temperate conditions) [181]. To date, only one study has reported an adverse effect of CHO 624 
ingestion during exercise (1 hour 70% VO2max running in 35°C and 12-20% RH) on GI barrier 625 
integrity, with ingestion of a multi-transportable  CHO gel (18 g maltodextrin and 9 g fructose) 626 
20-minutes into exercise shown to increase GI barrier integrity (I-FABP and endotoxin) loss 627 
relative to a placebo [194]. Surprisingly, in the placebo condition exertional-heat stress had 628 
no influence on GI barrier integrity, whilst in the CHO condition the magnitude of GI integrity 629 
loss was minimal. Currently little is known about the influence of pre-exercise CHO availability 630 
on GI barrier integrity. One study reported that 48-hour low (20% CHO, 65% fat) versus high 631 
(60% CHO, 25% fat) CHO-diet had no influence on GI MT after a laboratory duathlon [195]; 632 
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whilst a similar study reported no influence of a 24 hour low or high FODMAP diet on GI barrier 633 
integrity (I-FABP, LBP, sCD14-ST) following 2 hours of exertional-heat stress [147].  634 
Practical recommendations for CHO ingestion on GI barrier integrity are unable to be 635 
established at present, given the large variation in findings from seemingly comparable 636 
studies. This lack of consistency cannot be attributed to differences in prandial state, 637 
exercise intensity, CHO type/dose or participant demographic. In general, the application of 638 
traditional sports nutrition guidelines for CHO ingestion do not appear to adversely influence 639 
GI barrier integrity, and more likely would appear to offer favourable benefits. Future work 640 
is required to determine the most effective CHO formulations for fueling exercise and 641 
maintraining GI barrier integrity. Factors that may be important include: the carbohydrate 642 
source (e.g. potato, maize), dextrose equivalence, osmolarity, sugar profile and delivery 643 
format (e.g. drink, gel, energy chew, or bar). The impact of pre-exercise CHO status (e.g. low 644 
carbohydrate training, or fasted training) may also influence the GI barrier response to 645 
feeding. The strategy of gut-training (i.e. multiple exercise sessions with high [90 g·hour-1] 646 
CHO intake) to improve CHO tolerance during exercise does not appear to strengthen the GI 647 
barrier [191].  648 
Glutamine 649 
Glutamine is the most abundant amino acid in human tissue and plasma, where it 650 
performs numerous important regulatory functions. It is a conditionally essential nutrient 651 
during states of catabolic stress (e.g. starvation, trauma and severe infection), and is the major 652 
energy substrate of GI enterocytes. The use of L-glutamine supplementation to support GI 653 
barrier function has received extensive examination [196]. Benefits have repeatedly been 654 
shown in humans following large intravenous L-glutamine infusions (~0.2-0.5 g·kg·day-1) in 655 
patients with critical illness indicative of glutamine deficiency, including severe burns [197-656 
198], post-infectious irritable bowel syndrome [199], and major abdominal trauma [200]. In 657 
comparison, benefits are less prominent with low dose oral ingestion (<0.2 g·kg·day-1) in 658 
chronic GI diseases patients, whom are unlikely to be glutamine deficient and/or exposed to 659 
acute stress [201-202]. Mechanisms of action appear multifactorial including: increased 660 
epithelial cell proliferation [203]; upregulation of cytoprotective intracellular heat shock 661 
protein (I-HSP) expression [204]; modulation of inflammatory signalling pathways [205]; 662 
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increased vasodilating factors (e.g. nitric oxide); GI microbiota regulation [206]; enhanced GI 663 
glutathione status [207]; and improvement in TJ stability through increased expression of 664 
multiple TJ proteins [208-209]. 665 
Supplementation with L-glutamine is not presently endorsed by sports nutrition 666 
guidelines, on the basis of weak evidence demonstrating improved immune function [190] or 667 
exercise-performance [210]. Early research investigating the effect of L-glutamine 668 
supplementation on exercise-induced GI permeability (assessed with DSAT), found no 669 
additional benefit of co-administering L-glutamine (0.018 g·kg-1 BM) with CHO (0.18 g·kg-1BM) 670 
every 10 minutes during a one-hour moderate-intensity run (70% VO2max), in comparison to 671 
CHO alone [122]. Unfortunately, L-Glutamine was not assessed in isolation and the total dose 672 
consumed was only circa 8-12 g. Since then, researchers have changed their focus from low 673 
dose L-glutamine supplementation to maintain circulating concentrations, to provision of large 674 
oral doses to saturate the GI tissue prior to exercise. Both chronic (3x 0.3 g·kg·FFM-1 for seven 675 
days; [211]) and acute (0.9 g·kg·FFM-1 two-hours pre-exercise [116]) L-glutamine ingestion 676 
raised circulating concentrations by ~2.5-fold (suggestive of GI saturation) and attenuated the 677 
rise in the GI permeability (DSAT ratio) from basal conditions following a one-hour moderate-678 
intensity run (70% VO2max) in the heat (30°C/12-20% RH). Using an identical experimental-679 
design, it was subsequently shown that L-glutamine doses of 0.25, 0.5 and 0.9 g·kg·FFM-1 680 
supressed the post exertional-heat stress rise in serum I-FABP concentration (~0-20%) and 681 
DSAT ratio (~25-40%). Although the authors reported a dose-dependent effect on GI barrier 682 
integrity [212], statistical significance testing was not undertaken, with these conclusions 683 
drawn from magnitude based inference analysis. Recently, ingestion of 0.9 g·kg·FFM-1 of L-684 
glutamine one hour prior to a 20 km cycling time trial in the heat (35°C, 50% RH) blunted the 685 
rise in circulating post-exercise I-FABP, although this studies conclusions were drawn from a 686 
linear mixed methods Bayesian statistical approach [213].  687 
Practical recommendations support the use of a single L-glutamine dose (0.90 688 
g·kg·FFM-1) two-hours pre-exercise to protect GI barrier integrity. Given the requirement to 689 
only ingest a single acute-dose in the hours prior to exertional-heat stress, the 690 
supplementation protocol has clear real-world application in terms of both implementation 691 
logistics and expense. Further work is required to confirm these findings following more 692 
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severe exertional-heat stress protocols and extending analysis to include secondary markers 693 
of GI MT. The oral tolerance and safety of such large L-glutamine doses requires clinical 694 
assessment as it is above general guidelines (5-10 g) for sports supplements [214]. Likewise, 695 
a limitation of all previous research has been the performance of trials in the fasted state, 696 
whereby positive findings are potentially attributable to improvement in post-prandial 697 
splanchnic perfusion, rather than any benefits directly related to L-glutamine. Indeed, 698 
ingesting 15 g·20 min-1 of whey protein hydrolysate during a 2-hour moderate-intensity (60% 699 
VO2max) run in the heat (35°C/30% RH) has also been shown to be highly effective in 700 
maintaining GI barrier integrity [193]. Future research should focus on determining if 701 
specific amino acid mixtures are as effective, or can even outperform L-glutamine alone, for 702 
maintaining GI barrier integrity. 703 
Bovine Colostrum 704 
Bovine colostrum (BC) is the milk produced by cows during the first 24-48 hours post-705 
partum, and its composition markedly differs from milk produced later in lactation [215]. In 706 
humans, colostrum provides many health benefits to the neonate, including rapid tissue 707 
development and immune defence [216]. BC contains a variety of growth factors (e.g. insulin-708 
like growth factor-1; IGF-1) and immunomodulatory components (e.g. immunoglobulins, 709 
cytokines) at higher concentrations than human colostrum [217]. The use of a BC nutritional 710 
supplement (liquid and powder) to maintain GI barrier function in healthy adults has been 711 
shown to reduce GI permeability post NSAID administration [218], and can blunt systemic 712 
elevations in endotoxin following critical illness [219]. These findings are supported by in vitro 713 
studies on Caco-2 cells, where BC blunted GI cell apoptosis and increased epithelial resistance 714 
during heat exposure [113, 220]. Mechanisms of action include: increased epithelial cell 715 
proliferation [113, 221], upregulation of cytoprotective I-HSP expression [114] and improved 716 
TJ stability through a reduction in phosphorylated tyrosine concentrations of occludin and 717 
claudin-1 [114]. 718 
Supplementation with BC has increased in athletic populations in response to recent 719 
evidence of enhanced muscle growth rates [222], blunted exercise-associated 720 
immunosuppression [223] and improved exercise performance [224]. More recent 721 
investigations have assessed the influence of BC on exercise-induced GI damage. In a series 722 
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of experiments, 14 days of BC (20 g·day-1) halved the 3-fold rise in urinary DSAT ratio and 723 
circulating I-FABP concentrations following short-duration (20 minutes) high-intensity 724 
running (80% VO2max) [113, 114, 225]. Whilst these results show promise, such benefits 725 
appear attenuated by more demanding exercise protocols. Two comparable studies 726 
reported no effect of either a moderate (14 days at 20 g·day-1; [226] or high (7 days at 1.7 727 
g·kg·day-1 (circa ~120-150g); [152]) BC dosing on I-FABP concentrations following a fatiguing 728 
run in the heat (35-40°C; 50% RH). Likewise, March et al. [105], using their earlier BC 729 
supplementation protocol [225], found only minor (~10%) suppression of I-FABP 730 
concentration and a non-significant blunting of circulating bacteroides DNA following a 1-731 
hour run (70% VO2max) in the heat (30°C/60% RH).  732 
Practical recommendations support a BC dose of 20 g.day-1 for 14 days to protect the 733 
GI tract during moderately demanding exercise, though little-to-no benefits appear likely 734 
during more intense exercise. Two days of BC supplementation with the same daily dose 735 
offered no protective benefits [144]. Chronic low dose (500 mg·day-1) BC ingestion improved 736 
resting GI permeability (DSAT ratio) in athletes during heavy training [227], but chronic high 737 
dose (60 g·day-1) BC ingestion appeared to increase GI permeability [228]. Further work is 738 
required to determine the optimal time-course and BC dose to support GI barrier function. 739 
As there are large inter-manufacturer variations in BC formulations, future research should 740 
include accurate characterisation of the bioactive components in intervention trials, as 741 
these components are likely to have a significant bearing on study findings [229]. No studies 742 
have successfully measured the influence of BC on secondary GI MT post-exercise. BC 743 
appears to be well-tolerated in healthy individuals in doses up to 60 g·day-1 over several 744 
weeks, and although IGF-1 is on the World Anti-Doping Agency banned substance list, it is 745 
unlikely BC can result a positive doping control [230]. 746 
Nitric Oxide  747 
The free radicle gas, Nitric Oxide (NO), performs multiple signalling roles in the body. 748 
Synthesis occurs through two complementary pathways: the NO synthase (NOS) dependant L-749 
arginine pathway; and the NOS independent nitrate (NO3), nitrite (NO2), NO serial reduction 750 
pathway [231]. Supplementation with NO precursors, including L-arginine [232], L-citrulline 751 
and inorganic NO3 [233], are all capable of upregulating NO bioavailability across the 752 
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splanchnic organs. Rodent models show this increase in NO blunts GI histopathological 753 
damage and subsequent MT following NSAID ingestion [234], small bowel obstruction [235] 754 
and experimentally induced ischemic-reperfusion injury [236-237]. The vasodilatory role of 755 
NO in maintaining GI microcirculation appears to be one of the main mechanisms [82], with  756 
enhanced antioxidant scavenging [238], constrained neutrophil activation [239] and increased 757 
GI TJ protein expression [240] as complementary pathways.  758 
No guidelines exist for L-arginine or L-citrulline supplementation in athletic populations 759 
[241], and consensus documents do not support its use to improve oxygen uptake kinetics or 760 
exercise performance [242]. Only two studies have investigated the influence of nitric oxide 761 
precursurs on exercise-induced GI barrier integrity loss. A rodent study found addition of 2% 762 
L-arginine to the standard diet (over seven days) prevented a rise in GI barrier loss relative to 763 
the control following ~1-hour forced running to fatigue in the heat (34°C) [243]. Similarly in 764 
humans, Van Wijck et al. [127] found acute L-citrulline supplementation (10g given 30 minutes 765 
pre-exercise) successfully maintained splanchnic perfusion and blunted the rise in systemic I-766 
FABP during one hour of moderate intensity cycling (70% wattmax). However, this intervention 767 
did not reduce peak post-exercise I-FABP concentrations, or the urinary DSAT ratio. 768 
Inorganic NO3 supplementation has increased in athletic populations over the last 769 
decade [241]. Its popularity is founded upon evidence showing NO3 supplementation (~ 8 770 
mmol, acutely and chronically) reduces the oxygen cost of exercise, enhances muscle 771 
efficiency and improves prolonged aerobic performance (10-40 minutes) [244]. There is 772 
limited evidence addressing NO3 supplementation and exercise-induced GI barrier integrity 773 
loss. One placebo controlled study found acute sodium NO3 (800 mg given 2.5 hours pre-774 
exercise), did not attenuate the rise in ciculating I-FABP or LBP concentration concentration 775 
following  1-hour of moderate intensity cycling (70% wattmax) [131].  776 
Practical recommendations regarding the use of L-arginine, L-citrulline or inorganic 777 
NO3 to protect the GI tract during exercise are inconclusive. Further work is required to 778 
substantiate present findings and to verify any benefits over a range of exercise protocols. 779 
Likewise, evidence is required to confirm whether benefits are observed in highly-trained 780 
populations (who tend not to respond to NO supplementation), and to determine which NO 781 
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precursors provide the most effective GI protection. A further practical consideration is the 782 
apparent impaired thermoregulation associated with reduced cutaneous vasodilation, which 783 
might disrupt the GI barrier especially when exercising in the heat [245-246]. 784 
Probiotics 785 
Probiotics are live microorganisms considered to regulate the GI microbiota, which 786 
might confer health benefits when consumed in adequate quantities [247]. They are found in 787 
low concentrations across various food sources (e.g. non-pasteurised dairy products), and 788 
regular consumption has been recommended in patients with GI conditions since the early 789 
1900s [247]. More recently, probiotic supplementation to support GI barrier function has 790 
received extensive examination. Whilst positive barrier effects are reported in ~50% of human 791 
studies, these are not universal, and may refect the large variations in dose and strains 792 
administered [248-249]. Inconclusive effects are also reported in vitro on GI cellular apoptosis 793 
and epithelial integrity when Caco-2 cells are cultured with probiotics prior to insult [250-251]. 794 
Mechanisms of action are incompletely understood, but are believed to include: inhibition of 795 
pathogenic bacterial overgrowth; competition with pathogenic bacteria for binding sites on 796 
mucins and/or epithelial cells; increased mucosal immunoglobulin and antimicrobial proteins 797 
secretion; increased epithelial cell proliferation; upregulated I-HSP concentrations; 798 
suppressed local GI inflammation; and increased TJ stability through upregulation of GI TJ 799 
protein expression (for review see: [252]).  800 
Probiotic supplementation is increasingly popular in athletic populations, despite 801 
inconsistent effects of their use for either maintaining immune health or improving exercise 802 
performance [253]. With respect to GI barrier integrity, four weeks daily consumption of a 803 
multi-strain probiotic (45 x 109 colony forming units [CFU]; from three strains) blunted DSAT 804 
ratios (8%) and circulating endotoxin concentrations (~12%) following a ~35-minute 805 
fatiguing run (80% ventilatory threshold) in the heat (35°C/40% RH) [261]. A follow-up study 806 
reported daily ingestion of a similar multi-strain probiotic (3 x 109 CFU; from nine strains) 807 
for a period of twelve weeks approximately halved basal endotoxin concentrations 808 
immediately prior to and 6-days following an ultra-triathlon [254]. In contrast, seven days 809 
high-dose single strain probiotic supplementation (45 x 1011 CFU.day-1 Lactobacillus Casei) 810 
was associated with an increased rise in endotoxin concentrations, compared with placebo, 811 
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following two hours moderate-intensity running (60% VO2max) in the heat (34°C/32% RH) 812 
[149]. Similarly, the daily ingestion of another single strain probiotic (35 x 109 CFU 813 
Bifidobacterium longum) had no effect on resting endotoxin concentrations following six 814 
weeks of pre-season training in collegiate swimmers [255]. Likewise, four weeks daily 815 
supplementation with a multi-strain probiotic (25 x 109 CFU; from five strains) had no 816 
influence on either DSAT, I-FABP or sCD14 responses following a simulated 42.2 km 817 
marathon in temperate conditions [148]. Finally, four weeks supplementation with a single 818 
strain probiotic (2 x 108 CFU Lactobacillus Salivarius) had no influence on DSAT responses, 819 
(or faecal microbial composition), following two hours of moderate intensity running (60% 820 
VO2max) in temperate conditions [256]. It is unlikely the final two studies were sufficiently 821 
powered to detect any influence of probiotic supplementation of GI barrier integrity. 822 
The present data indicate that probiotic supplementation has little for supporting GI 823 
barrier integrity in response to exericse. It is not possible to elucidate whether incosistant 824 
responses are attributable to the specific probiotic strain, duration of supplementation or 825 
another factor. Future research is required to develop probiotic supplementation regimes and 826 
will need to address factors such as strain(s), timing and dose. It will alos be necessary to verify 827 
potential efficacy using relevant exercise (heat stress) protocols. Global metabolomics 828 
approaches have linked exercise-induced GI barrier function loss with alterations in GI 829 
microbiota composition during a four-day military arctic training exercise (51 km ski march; 830 
[257]), and such methodologies should be applied when developing probiotic supplements to 831 
support GI barrier integrity. Probiotic use is considered safe in healthy populations, when 832 
consumed acutely and chronically [253].  833 
Polyphenols  834 
Polyphenols are natural compounds that defend plants against damage from radiation 835 
and pathogens. Over 8000 polyphenols have been identified, which are classified into four 836 
major groups: flavonoids; phenolic acids; stilbenes; and lignans. Quercetin is the most 837 
abundant dietary flavonoid polyphenol [258], and in rodents’ supplementation has been 838 
shown to maintain GI barrier integrity [259]. However, in vitro evidence from human Caco-2 839 
cells is less conclusive, with quercetin shown to both improve [260-261] and impair [262-263] 840 
GI barrier integrity in response to heat stress. Proposed mechanisms in favourable studies 841 
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include modulation of vasodilatory factors (e.g. NO [263]), elevated antioxidant scavenging 842 
[265] and improved TJ stability through upregulation of several TJ proteins [266]. Proposed 843 
mechanisms in non-favourable studies relate to reduced cytoprotective I-HSP expression 844 
[267] and TJ stability through disruption in occludin TJ protein localisation [262]. Both positive 845 
and negative responses have been comparatively reported when Caco-2 cells are 846 
supplemented in vitro with additional polyphenols [264, 266]. Human studies assessing 847 
polyphenol supplementation efficacy on GI barrier integrity are lacking [264], and where in 848 
vitro studies administerphysiologically relevant polyphenol doses the effects have been 849 
negligible [268].  850 
Polyphenol supplementation is increasingly popular in athletic populations [269]. This 851 
is founded upon moderate evidence of enhanced skeletal muscle recovery from micro-852 
damage [270], blunted exercise-associated immunosuppression [271] and in some cases 853 
improved (1-3%) endurance exercise performance [272]. With respect to polyphenol 854 
supplementation and exercise-induced GI barrier integrity, the effect of daily quercetin 855 
supplementation (2 g·day-1 one hour pre-exercise) on GI permeability following the first and 856 
seventh days of a standardised isothermic walking (100 minutes; 1.8 m·s-1 in 46°C/20% RH) 857 
heat acclimation regime was assessed [143]. On both days, quercetin ingestion stimulated a 858 
~two-fold rise in urinary lactulose and plasma endotoxin compared with a placebo condition. 859 
More promisingly, supplementation with curcumin (3 days of 0.5 g·day-1), a constituent of 860 
turmeric, blunted circulating I-FABP concentrations by ~30% after one-hour moderate 861 
intensity running (65% VO2max) in the heat (37°C/25% RH; [273]).  862 
There are no practical recommendations supporting polyphenol use to protect the GI 863 
tract during strenuous exercise. Despite promising in vitro observations, more work is required 864 
to determine the optimal formulation, time-course and polyphenol dose to support GI barrier 865 
function across different exercise-modalities. No studies have successfully measured the 866 
effect of polyphenols on secondary GI MT post-exercise and clearly future studies should 867 
attempt to control for dietary polyphenol intake.  868 
Zinc-Carnosine 869 
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Zinc-Carnosine (ZnC) is a pharmaceutical chelate of zinc and L-carnosine [274]. It is 870 
widely used in Japan to treat gastric ulcers [275], and more recently has been marketed in 871 
Europe to support GI health [276]. Zinc is an essential trace element and a co-factor in 872 
numerous tissue regenerative and immunomodulatory enzymatic reactions [277], whilst L-873 
carnosine is a cytoplasmic dipeptide of beta-alanine and L-histidine [278]. Daily ZnC ingestion 874 
improves GI barrier integrity in healthy humans following chronic GI barrier damaging NSAID 875 
ingestion [276, 279]. These protective benefits are reported to be synergistic compared with 876 
consuming either ingredient individually [280]. In vitro studies of rat intestinal and human 877 
Caco-2 cells support these reports, where ZnC blunts GI cellular apoptosis [281-282] and 878 
increases epithelial electrical resistance [114] upon damage, in a dose-dependent fashion. 879 
Mechanisms of action appear multifactorial, including increased: epithelial cell proliferation 880 
[276]; I-HSP concentrations [114]; antioxidant activity [283]; and stability of TJs through 881 
blunting phosphorylated occludin and claudin-1 expression [114]. 882 
No guidelines exist concerning ZnC supplementation in athletic populations. Athletes 883 
are recommended to ensure sufficient dietary zinc ingestion (EU RDA = 10 mg·day-1) to 884 
prevent deficiencies, and to supplement with large oral doses (~75 mg·day-1), when suffering 885 
from acute upper respiratory tract infection to accelerate recovery [190]. Though L-Carnosine 886 
supplementation is uncommon, supplementing β-alanine (~65 mg·kg·day-1) the rate-limiting 887 
precursor for muscle L-carnosine synthesis, has been shown to increase muscle carnosine 888 
stores [283]. To date, only one study has investigated the influence of ZnC on exercise-induced 889 
GI damage. Fourteen days of ZnC (75 mg·day-1) attenuated a 3-fold rise is DSAT ratio by 70% 890 
after short-duration (20 minutes) high-intensity running (80% VO2max) [114]. This effect was 891 
comparable to that observed with BC (20 g·day-1 for 14 days) in the same study, and when the 892 
two-treatments were combined the benefits appeared synergistic (85% reduction DSAT ratio). 893 
Furthermore, the combination of ZnC and BC blunted the exercise-induced increase in DSAT 894 
ratio by 30% after only two-days, whilst no protection was offered by either ingredient alone 895 
at this point [114]. 896 
Practical recommendations support ZnC use at a dose of 75 mg·day-1 for 14 days to 897 
protect the GI tract during moderately demanding exercise. Further work is needed to 898 
substantiate existing findings and verify the potential benefits of ZnC during more strenuous 899 
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exercise. No studies have successfully measured the influence of ZnC on secondary GI MT 900 
post-exercise. Research is required to determine the optimal time-course and dose of ZnC to 901 
support GI barrier function with chronic and acute supplementation. Larger doses of ZnC 902 
(150 mg·day-1) appear well-tolerated in GI disease patients in the short-term [285], and 903 
dose-dependent in vitro evidence suggests this might offer greater protection [280]. Co-904 
ingestion of copper with zinc (1:10 ratio or 2 mg·day-1) appears to prevent zinc inhibiting  905 
copper absorption [190].  906 
Limitations and Future Directions 907 
Investigation of nutritional countermeasures that support GI barrier integrity during 908 
strenuous exercise is an important and expanding area of research. Preliminary observations 909 
indicate some diet regimens and dietary supplements could benefit exercising populations. 910 
Optimal supplementation strategies should be safe, well-tolerated, practical (e.g. 911 
affordable/low mass), fast acting and effective in a wide range of scenarios (e.g. exercise 912 
intensity/duration, population). It is also important that they are without secondary adverse 913 
responses, especially thouse relating to skeletal muscle adaptation, thermoregulation, 914 
immune function, bone health etc. Whilst there are numerous examples of well-conducted 915 
studies reporting beneficial effects from diet regimens and individual supplements on GI 916 
barrier integrity, it is currently not possible to provide definitive guidance. In part this is due 917 
to limitations and variations in study designs and in some instance’s incomplete 918 
characterisation of the bioactive nutrients. 919 
Future research should address diet regimens/nutritional supplements that satisfy the 920 
above requirements when tested in the most demanding scenarios (e.g. high 921 
intensity/prolonged exertional-heat stress). It would appear very worthwhile to assess the 922 
synergy between ingredients that maintain GI integrity, especially if they are though to act via 923 
different biochemical pathways. Further supplements that warrant future exploration include: 924 
omega-3 polyunsaturated fatty acids [286]; vitamin C [287]; vitamin E [287]; vitamin D [288] 925 
and prebiotics [289]. Research should target specific populations (e.g. gender, training status, 926 
heat-acclimated, GI disease), exercise modalities (especially prolonged duration), 927 
supplementation timings (e.g. repeat dosing, delayed/post-exercise ingestion) and monitor 928 
the continued efficacy of supplementation following chronic application. Of note, future 929 
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research is warranted to determine the most damaging exercise protocol on GI barrier, which 930 
possibly involves a combination of prolonged/intense exercise performed in the heat. 931 
From a methodological perspective, it is recommended that future studies assess a 932 
battery of relevant GI barrier integrity markers (e.g. DSAT, plus I-FABP/I-BABP/claudin-3, plus 933 
endotoxin/LBP/sCD14/bactDNA) and monitor alterations in the proposed mechanistic 934 
pathways (e.g. splanchnic perfusion, I-HSPs) underpinning any functional benefits. Key 935 
extraneous variables should be controlled, including: prandial state [180]; hydration status 936 
[135]; beverage temperature [137]; prior NSAID ingestion [121]; habitual diet and supplement 937 
use.  938 
Conclusions 939 
EHS is a life-threatening disease involving thermoregulatory failure, which sporadically 940 
arises in otherwise healthy individuals following performance of strenuous exercise or 941 
occupationally arduous tasks. Current EHS management policy primarily takes a 942 
thermoregulatory management approach despite evidence of MT following loss of GI barrier 943 
integrity being an important process in the disease pathophysiology. A range of techniques 944 
are available to assess GI barrier integrity in vivo, and a battery approach monitoring multiple 945 
measures in both field and research settings is recommended. The severity of GI barrier 946 
integrity loss following exertional-heat stress appears to be intensity and duration- 947 
dependant, with thermoregulatory strain being an additional risk factor. Considerations for 948 
the specific GI barrier integrity assessment technique must be made when interpreting 949 
individual studies conclusions, whereby I-FABP responses typically provided the greatest 950 
sensitivity. The specific aetiology of exertional-heat stress induced GI barrier integrity loss is 951 
poorly defined, but likely relates to the direct effects of localised hyperthermia, ischemia-952 
reperfusion injury and neuroendocrine-immune alterations. 953 
A range of nutritional countermeasures have been shown to positively affect GI 954 
barrier integrity following strenuous exercise and exercise-heat stress. However, despite 955 
rapid advancements in this field, definitive recommendations cannot be provided due to the 956 
heterogeneity of experimental designs. Nevertheless, promising effects have been 957 
associated with following general sports nutrition CHO supplementation guidelines during 958 
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exercise (30-100 g·h-1 liquid multi-transportable CHO), and acute L-glutamine ingestion two 959 
hours pre-exercise (0.25-0.9 g·kg·FFM-1). Benefits from BC, and probiotics likely relate to the 960 
specific supplement formulation, and hence require further investigation. Despite a sound 961 
rationale for the use of NO precursors and polyphenols to limit exercise-induced GI barrier 962 
integrity loss, substantive supporting evidence is currently absent. ZnC requires further 963 
verification, where short-term (1-3 days) high-dose supplementation appears an attractive 964 
consideration. Further well-controlled research in nascent areas could elucidate potential 965 
treatment options for exercise-induced GI barrier integrity loss.  966 
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Table 1. Overview of In Vivo techniques to assess GI Barrier Integrity 1957 
Abbreviations: HPLC, high performance liquid chromatography; MS, mass spectrometry; 1958 
ELISA, enzyme-linked immunosorbent assay; LAL, limulus amoebocyte lysate assay; PCR, 1959 
polymerase chain reaction  1960 
Technique Sample Method Site Limitations 
Active Techniques     
Dual-Sugar 
Absorption Test 
(DSAT) 
Urine or 
blood 
HPLC (+) 
MS 
Small GI 
Integrity 
Gold-standard. High reliability. Time-consuming 
(5 hr urine, >2.5 hour blood). No standard 
protocol with exercise. Well-studied. 
Multi-Sugar 
Absorption Test 
(MSAT) 
Urine or 
blood 
HLPC (+) 
MS 
Entire GI 
Integrity 
Gold-Standard. Segmental GI integrity. Time-
consuming (5 hr urine, >2.5 hour blood). No 
standard protocol with exercise. Few studies. 
Polyethylene Glycol 
(PEG) Absorption 
Test 
Urine HLPC (+) 
MS 
Entire GI 
Integrity 
Validated against MSAT. Can include multiple 
weight PEGs (e.g. 100, 400, 1000, 4000 kDa). 
Time-consuming (5 hr urine). Few studies.  
Passive Techniques     
Intestinal Fatty Acid 
Binding Protein (I-
FABP) 
Urine or 
Blood 
ELISA Epithelial 
injury 
Tissue specific (duodenum and jejunum). Short 
half-life (11 minutes). Weak correlations with 
DSAT. Well-studied.  
Ileal Bile-Acid 
Binding Protein (I-
BABP) 
Urine or 
Blood 
ELISA Epithelial 
injury 
Tissue specific (ileum). Few studies. Weak 
correlations with I-FABP. Few studies. 
Diamine Oxidase 
(DAO), α- 
Glutathione s-
Transferase (α-
GST), Smooth 
Muscle 22 (SM22) 
Blood ELISA Epithelial 
injury 
Non-tissue specific. Few studies.  
Claudin-3  
(CLDN3) 
Urine or 
Blood 
ELISA TJ 
Integrity 
Non-tissue specific. Few studies. 
Zonulin Blood or 
Faeces 
ELISA TJ 
Integrity 
Non-tissue specific. Assay cross-reactivity 
(complement C3). Moderate studies. 
Endotoxin  
(LPS) 
Blood LAL assay MT Tissue specific. Sample contamination causes 
false-positives. Hepatic removal and receptor 
binding cause false-negatives. Well-studied.   
LPS Binding Protein 
(LBP) 
Blood ELISA MT Tissue specific. Lower risk of false-positives than 
endotoxin. Indirect marker of endotoxin 
exposure. Influenced by hepatic production. 
Long half-life (12-14 hours). Few studies. 
Soluable-CD14 
(sCD14-ST) 
Blood ELISA MT Tissue specific. Lower risk of false positives than 
endotoxin. Influenced by hepatic production and 
monocytes shedding. Few studies. 
D-lactate Blood ELISA MT Predominately tissue specific. Economical and 
time efficient assessment. Potentially influenced 
by methylglyoxal metabolism. Few studies.  
16s Bacterial rDNA 
(bactDNA) 
Blood Real-time 
PCR assay 
MT Tissue specific. Novel. Lower risk of false-
positives than endotoxin. Potential for regional 
integrity assessment. Few studies.  
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Table 2. Influence of acute exercise-(heat) stress on small-intestine DSAT responses 1961 
Author Subjects Exercise Protocol Peak 
TCore (°C) 
Mean 
HR 
(bpm) 
Biofluid, DSAT 
L/R or L/M 
(timepoint)  
van 
Nieuwenh-
oven et al. 
[110] 
10 male 
(MT) 
90 minutes cycling at 70% Wattmax 
(fasted) in Tamb 19°C (RH = N/A)  
N/A N/A Urine L/R (5hr): 
0.007 s  
van 
Nieuwenh-
oven et al. 
[118] 
10 male 
(MT) 
90 minutes cycling at 70% Wattmax 
(fasted) in Tamb 19°C (RH = N/A)  
38.8 N/A Urine L/R (5hr): 
0.008 nb, c 
Nieman et al. 
[107]  
20 male 
and female 
(UT) 
45 minutes walking uphill (5% grade) 
at 60% VO2max (fasted) in Tamb not 
reported 
N/A 132 Urine L/R (5hr): 
0.009 nb, c 
Smetanka et 
al. [123] 
8 male 
(HT) 
Chicago marathon (42.2 km) in Tamb 
(fed) 22°C (48% RH) 
N/A N/A Urine L/R (5hr): 
0.020 ns 
Shing et al. 
[126] 
10 male 
(HT)  
~33 minutes running to fatigue at 80% 
VE (fed) in Tamb 35°C (40% RH)  
39.4 172 Urine L/R (5hr): 
0.022 nb, c 
Janssen-
Duijghuijsen 
et al. [109] 
11 male 
(HT) 
90 minutes cycling at 50% wattmax 
(fed) in Tamb not reported following a 
sleep-low glycogen depletion regime 
N/A N/A Urine L/R (5hr): 
~0.022 ns 
Plasma L/R (1hr): 
~0.110 s 
Snipe et al. 
[115, 125] 
6 male and 
4 female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 22°C (44% RH) 
38.5 ~150 Urine L/R (5hr): 
0.025 nb 
Snipe et al. 
[125] 
6 male and 
4 female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 30°C (25% RH) 
38.6 ~155 Urine L/R (5hr): 
0.026 nb 
van Wijck et 
al. [127]  
10 male 
(MT) 
60 minutes cycling at 70% wattmax 
(fasted) in Tamb not reported 
N/A N/A Urine L/R (2hr): 
0.027 nb,c 
Snipe and 
Costa [291] 
13 female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (25% RH) 
38.8 ~155 Urine L/R (5hr): 
0.028 nb 
Ryan et al. 
[120] 
7 males 
(MT) 
60 minutes running at 68% VO2max 
(fasted) in Tamb not reported 
N/A N/A Urine L/M (6hr): 
0.029 ns 
van 
Nieuwenh-
oven et al. 
[112] 
9 male and 
1 female 
(MT) 
90 minutes cycling at 70% Wattmax 
(fasted) in Tamb 19°C (RH = N/A)  
N/A N/A Urine L/R (5hr): 
0.030 ns 
van Wijck et 
al. [124]  
9 male 
(MT) 
60 minutes cycling at 70% wattmax 
(fasted) in Tamb not reported 
N/A N/A Urine L/R (2hr): 
0.030 s, c 
Pugh et al. 
[88] 
11 male 
(MT-HT) 
18x 400 metre sprint at 120% VO2max 
(fed) in Tamb not reported 
N/A N/A Urine L/R (2hr): 
0.030 ns 
Serum L/R (2hr): 
~0.051 s 
Snipe and 
Costa [291] 
11 male 
(MT)  
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (25% RH) 
39.1 ~150 Urine L/R (5hr): 
0.030 nb 
Buchman et 
al. [290]  
17 male 
and 2 
female 
Competitive Marathon (fed) in Tamb 
2°C with freezing rain 
N/A N/A Urine L/R (6hr): 
0.030 ns, c 
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Snipe et al. 
(Part B) [115] 
6 male and 
4 female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (26% RH) 
39.6 ~170 Urine L/R (5hr): 
0.032 nb 
Snipe et al. 
[193] 
6 male and 
5 female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (30% RH) 
39.3 159 Urine L/R (5hr): 
0.034 nb, c 
March et al. 
[225] 
9 male 
(MT)  
20 minutes running at 80% VO2peak 
(fasted) in Tamb 22°C (37% RH) 
38.4 170 Urine L/R (5hr): 
0.035 s, c 
Pals et al. 
(Part A) [108] 
5 male and 
1 female 
(MT) 
60 minutes running at 40% VO2peak 
(fasted) in Tamb 22°C (50% RH) 
38.0 N/A Urine L/R (5hr): 
0.036 ns 
Marchbank et 
al. [113] 
12 male 
(MT) 
20 minutes running to fatigue at 80% 
VO2max (fasted) in Tamb not reported 
38.3 N/A Urine L/R (5hr): 
0.038 s, c 
van 
Nieuwenh-
oven et al.  
[111] 
9 male and 
1 female 
(MT) 
90 minutes running at 70% VO2max 
(fasted) in Tamb 19°C (RH = N/A) 
N/A N/A Urine L/R (5hr): 
0.040 s 
van Wijck et 
al. [86] 
6 male 
(HT) 
60 minutes cycling at 70% wattmax 
(fasted) in Tamb not reported 
N/A N/A Urine L/R (5hr): 
0.040 ns 
Plasma L/R 
(2.4hr): 0.060 s 
Lambert et al. 
(Part A) [119] 
11 male 
and 9 
female 
(MT) 
60 minutes running at 70% VO2max 
(fasted) in Tamb 22°C (48% RH) 
38.5 N/A Urine L/R (5hr): 
0.049 ns, c 
Lambert et al. 
[122] 
13 male 
and 4 
female 
(HT) 
60 minutes running at 70% VO2max 
(fasted) in Tamb 22°C (48% RH) 
38.3 N/A Urine L/R (5hr): 
0.050 nb, c 
Zuhl et al. 
[211] 
4 male and 
3 female 
(LT/MT) 
60 minutes running at 70% VO2max 
(fasted) in Tamb 30°C (12-20% RH) 
39.4 N/A Urine L/R (5hr): 
0.060 nb, c  
Zuhl et al. 
[116] 
2 male and 
5 female 
(LT/MT) 
60 minutes running at 70% VO2max 
(fasted) in Tamb 30°C (12-20% RH) 
39.5 N/A Urine L/R (5hr): 
0.060 nb, c 
Lambert et al. 
(Part B) [119] 
11 male 
and 9 
female 
(MT) 
60 minutes running at 70% VO2max 
(fasted) in Tamb 22°C (48% RH) without 
fluid ingestion 
38.5 N/A Urine L/R (5hr): 
0.063 s, c 
Pals et al. 
(Part B) [108] 
5 male and 
1 female 
(MT) 
60 minutes running at 40% VO2peak 
(fasted) in Tamb 22°C (50% RH) 
38.7 N/A Urine L/R (5hr): 
0.064 ns 
Lambert et al. 
[121] 
8 male 
(MT) 
60 minutes running at 70% VO2max 
(fasted) in Tamb 22°C (48% RH) 
38.3 N/A Urine L/R (5hr): 
0.065 nb, c 
Buchman et 
al. [287] 
15 male 
and female 
(LT-HT) 
Road marathon (42.2 km) (fed) in Tamb 
not reported 
N/A N/A Urine L/M  (6hr): 
0.070 ns, c 
Pugh et al. 
[212] 
10 male 
(MT) 
60 minutes at 70% VO2max running 
(fasted) in Tamb 30°C (4-45% RH) 
38.5 82.5% 
of max 
Serum L/R (2hr): 
~0.080 s, c 
Pugh et al. 
[148] 
10 male 
and 2 
female 
(MT) 
42.4 km track marathon (247 ± 47 
minutes; fed) in Tamb 16-17°C (N/A RH) 
N/A ~160 Serum L/R (1hr) 
0.081 (37%) s, c 
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Lambert et al. 
[292] 
12 female 
(LT-HT) 
Hawaii Ironman (fed) in Tamb not 
reported 
N/A N/A Urine L/R (5hr): 
0.087 nb 
Davison et al. 
[114] 
8 male 
(MT/HT) 
20 minutes running to fatigue at 80% 
VO2max (fasted) in Tamb not reported 
39.3 ~170 Urine L/R (5hr): 
0.098 s, c 
Janssen-
Duijghuijsen 
et al. [293]  
4 male and 
6 female 
(LT) 
60 minutes cycling at 70% wattmax 
(fed) in Tamb not reported 
N/A N/A Plasma L/R (1hr): 
~0.100 s  
Lambert et al. 
[292] 
29 male 
(LT-HT) 
Hawaii Ironman (fed) in Tamb not 
reported 
N/A N/A Urine L/R (5hr): 
0.105 nb 
Pals et al. 
(Part C) [108] 
5 male and 
1 female 
(MT) 
60 minutes running at 40% VO2peak 
(fasted) in Tamb 22°C (50% RH) 
39.6 N/A Urine L/R (5hr): 
0.107 s 
LT = Low-trained (35-49 ml·kg·min-1 VO2max); MT = Moderate-trained (50-59 ml·kg·min-1 1962 
VO2max); HT = High-trained (60+ ml·kg·min-1 VO2max). s = significant change post-exercise (p < 1963 
0.05); ns = non-significant change post-exercise (p >0.05); nb = no baseline resting data to 1964 
compare against; c = control/placebo trial of study 1965 
 1966 
 1967 
 1968 
 1969 
 1970 
 1971 
 1972 
 1973 
 1974 
 1975 
 1976 
 1977 
 1978 
 1979 
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Table 3. Influence of acute exercise-(heat) stress on systemic I-FABP concentrations 1980 
Reference Subjects Exercise Protocol Peak 
TCore (°C) 
Mean 
HR 
(bpm) 
FABP2 (Δ pre-to-
post exercise) 
Janssen-
Duijghuijsen et 
al. [109] 
11 male 
(HT) 
90 minutes cycling at 50% wattmax 
(fed) in Tamb not reported following a 
“sleep-low” glycogen depletion 
regime 
N/A N/A ~-90 pg·ml-1    (~-
65%) c 
Kartaram et al. 
(Part A) [129] 
15 male 
(MT) 
60 minutes cycling at 50% wattmax 
(fed) in Tamb not reported  
N/A N/A ~-50 pg·ml-1     
(~-10%) ns 
Lee and Thake 
(Part A) [128] 
7 male 
(MT) 
60 minutes cycling at 50% VO2max (fed) 
in Tamb 18°C (35% RH) on day one of 
temperate acclimation 
37.9 133 28 pg·ml-1        
(8%) ns,c 
Trommelen et 
al. [130] 
10 male 
(HT) 
180 minutes cycling at 50% wattmax 
(fasted) in Tamb 18-22°C (55-65% RH) 
N/A N/A N/A pg·ml-1  
(20%) ns,c 
Edinburgh et 
al. (Part A) 
[180] 
12 male 
(MT) 
60 minutes cycling at 50% VO2max (fed) 
in Tamb 18°C (35% RH) 
N/A N/A 70 pg·ml-1 
(34%) s 
Edinburgh et 
al. (Part B) 
[180] 
12 male 
(MT) 
60 minutes cycling at 50% VO2max 
(fasted) in Tamb 18°C (35% RH) 
N/A N/A 88 pg·ml-1 
(20%) s 
Osborne et al. 
(Part A) [133] 
8 male 
(MT-HT) 
30 minutes cycling at 50/70% Wattmax, 
then 30 minutes at 50% wattmax 
(fasted) in Tamb 20°C (55% RH) 
38.5 139 138 pg·ml-1 
(29%) ns 
Salvador et al. 
2019 [181] 
12 male 
(MT-HT) 
120 minutes cycling at 60% VO2max 
(fed) then 30-40 minutes (20 km) time 
trial in Tamb not reported 
37.9 ~168 N/A pg·ml-1 
(~50%) s, c 
van Wijck et 
al. [127] 
10 male 
(MT) 
60 minutes cycling at 70% wattmax 
(fasted) in Tamb not reported 
N/A N/A 153 pg·ml-1 
(72%) s 
Nava et al. 
[294] 
7 male 
and 4 
female 
(LT-MT) 
56 minutes mixed intensity (~55% 
VO2max) discontinuous firefighting 
exercises (fed) in Tamb 38°C (35% RH) 
on day one of two 
38.7 ~161 ~160 pg·ml-1 
(23%) ns, c 
Van Wijck et 
al. [124] 
9 male 
(MT) 
60 minutes cycling at 70% wattmax 
(fasted) in Tamb not reported 
N/A N/A 179 pg·ml-1 
(61%) s 
Lee et al. (Part 
C) [128] 
7 male 
(MT) 
60 minutes cycling at 50% VO2max (fed) 
in Tamb 18°C (35% RH) and FiO2 = 
0.14% on day one of hypoxic 
acclimation 
38.2 149 193 pg·ml-1 
(43%) s,c 
Lis et al. [295] 13 male 
and 
female 
(MT) 
45 minutes cycling at 70% wattmax and 
15 min cycling time trial (fed) in 20°C 
(40% RH) 
N/A 168 210 pg·ml-1 
(223%) s,c 
Pugh et al. 
[148] 
10 male 
(MT) 
60 minutes at 70% VO2max running 
(fasted) in Tamb 30°C (4-45% RH) 
38.5 82.5% 
of HR 
max 
250 pg·ml-1 
(71%) s,c 
Snipe et al. 
(Part A) [115, 
125] 
6 male 
and 4 
female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 22°C (44% RH) 
38.5 ~150 274 pg·ml-1 
(127%) s 
Sheahen et al. 
(Part A) [136] 
12 male 
(MT) 
45 minutes running at 70% VO2max 
(fasted) in Tamb 20°C (40% RH) 
38.2 165 281 pg·ml-1 
(49%) s  
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Lee et al. (Part 
B) [128] 
7 male 
(MT) 
60 minutes cycling at 50% VO2max (fed) 
in Tamb 40°C (25% RH) on day one of 
heat acclimation 
38.7 151 282 pg·ml-1 
(76%) s,c  
Morrison et al. 
(Part B) [152] 
8 male 
(UT) 
30 minutes cycling at 50% heart rate 
reserve (HRR), 30 minutes jogging at 
80% HRR and 30 minute running time 
trial (fed) in Tamb 30°C (50% RH) 
38.6 N/A 283 pg·ml-1 
(276%) s,c 
Barberio et al. 
[72] 
9 male 
(MT) 
~24 minutes running at 78% VO2max 
(fed) in Tamb 40°C (40% RH) prior to 
heat acclimation 
39.0 N/A 297 pg·ml-1 
(46%) s,c 
Hill et al. [134] 10 male 
(MT) 
60 minutes running at 65% VO2max 
(fasted) in Tamb not reported 
N/A ~170 300 pg·ml-1 
(50%) ns,c 
van Wijck et 
al. [86] 
 
15 male 
(HT) 
60 minutes cycling at 70% wattmax 
(fasted) in Tamb not reported 
N/A N/A 306 pg·ml-1 
(61%) s  
Kashima et al. 
[296] 
5 male 
and 3 
female 
(MT) 
30 intermittent 20 second cycle 
sprints at 120% wattmax, with 40 
seconds recovery between each (fed) 
in 23°C (40% RH) 
N/A 150 343 pg·ml-1 
(266%) s 
Pugh et al. 
[88] 
11 male 
(MT-HT) 
18x 400 metre sprint at 120% VO2max 
(fed) in Tamb not reported 
N/A N/A 348 pg·ml-1 
(72%) s 
March et al. 
[225] 
9 male 
(MT)  
20 minutes running at 80% VO2peak 
(fasted) in Tamb 22°C (37% RH) 
38.4 170 350 pg·ml-1 
(61%) s,c 
Janssen-
Duijghuijsen et 
al. [293] 
4 male 
and 6 
female 
(LT) 
60 minutes cycling at 70% wattmax 
(fed) in Tamb not reported 
N/A N/A ~350 pg·ml-1 
(~77%) s,c 
Sheahen et al. 
(Part B) [136] 
12 male 
(MT) 
45 minutes running at 70% VO2max 
(fasted) in Tamb 30°C (40% RH) 
38.3 163 369 pg·ml-1 
(63%) s 
Costa et al. 
[135] 
11 male 
(MT-HT) 
120 minutes running at 70% VO2max 
(fed) in Tamb 25°C (35% RH) 
N/A 148 371 pg·ml-1 
(86%) ns,c 
Osborne et al. 
[213] 
12 male 
(MT-HT) 
33 minutes (20 km) cycling time trial 
(fasted) in 35°C (50% RH) 
39 167 441 pg·ml-1 
(83%) s,c 
Kartaram et al. 
(Part B) [129] 
15 male 
(MT) 
60 minutes cycling at 70% wattmax 
(fed) in Tamb not reported  
N/A N/A ~500 pg·ml-1   
(~66%) s 
Kartaram et al. 
(Part C) [129] 
15 male 
(MT) 
60 minutes cycling at 85/55% wattmax 
(fed) in Tamb not reported  
N/A N/A ~500 pg·ml-1   
(~66%) s 
McKenna et al. 
[226] 
10 male 
(MT) 
46 minutes running at 95% VE 
threshold (fasted) in Tamb 40°C (50% 
RH)  
39.7 N/A 516 pg·ml-1 
(52%) s,c 
Karhu et al. 
[132] 
 
17 male 
(MT-HT) 
90 minutes running at 80% of best 10 
km race time (fed) in Tamb not 
reported 
N/A N/A 531 pg·ml-1 
(151%) s  
Snipe and 
Costa [137] 
6 male 
and 6 
female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 30°C (35% RH) 
38.8 160 573 pg·ml-1 
(184%) s,c 
Snipe et al. 
(Part B) [125] 
6 male 
and 4 
female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 30°C (25% RH) 
38.6 ~155 ~ 580 pg·ml-1 
(184%) 
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Hill et al. [134] 10 male 
(MT) 
60 minutes running at 65% VO2max 
(fasted) in Tamb not reported (FiO2 = 
13.5%) 
N/A ~170 700 pg·ml-1 
(168%) ns,c 
Osborne et al. 
(Part B) [133] 
8 Male 
(MT-HT) 
30 minutes cycling at 50/70% Wattmax, 
then 30 minutes at 50% wattmax 
(fasted) in Tamb 35°C (53% RH) 
39.5 159 608 pg·ml-1 
(140%) s 
Szymanski et 
al. [273] 
6 male 
and 2 
female 
(LT/MT) 
60 minutes running at 68% VO2max 
(fasted) in Tamb 37°C (25% RH) 
39.0 174 800 pg·ml-1 
(87%) s,c 
Morrison et al. 
(Part A) [152] 
7 male 
(HT) 
30 minutes cycling at 50% heart rate 
reserve (HRR), 30 minutes jogging at 
80% HRR and 30 minute running time 
trial (fed) in Tamb 30°C (50% RH) 
38.6 N/A 806 pg·ml-1 
(663%) s,c 
Snipe et al. 
[193] 
6 male 
and 5 
female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (30% RH) 
39.3 159 897 pg·ml-1 
(288%) s,c 
Snipe et al. 
(Part B) [115] 
6 male 
and 4 
female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (26% RH) 
39.6 ~170 1230 pg·ml-1 
(432%) s 
Pugh et al. 
[148] 
10 male 
and 2 
female 
(MT) 
42.4 km track marathon (247 ± 47 
minutes; fed) in Tamb 16-17°C (N/A RH) 
N/A ~160 1246 pg·ml-1 
(371%) s, c 
March et al. 
[105] 
12 male 
(MT) 
60 minutes running at 70% VO2max 
(fasted) in Tamb 30°C (60% RH) 
39.3 170 1263 pg·ml-1 
(407%) s, c 
Snipe and 
Costa [291] 
11 male 
(MT)  
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (25% RH) 
39.1 ~150 1389 pg·ml-1 
(479%) s 
Snipe et al. 
[291] 
13 female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (25% RH) 
38.8 ~155 1445 pg·ml-1 
(479%) s 
Jonvik et al. 
[131] 
16 male 
(HT) 
60 minutes cycling at 70% wattmax 
(fasted) in Tamb not reported 
N/A N/A 1745 pg·ml-1   
(249%) s 
Gaskell et al. 
[147] 
10 male 
and 8 
female 
(MT-HT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (25% RH) 
38.6 ~151 1805 pg·ml-1   
(710%) s, c 
LT = Low-trained (35-49 ml·kg·min-1 VO2max); MT = Moderate-trained (50-59 ml·kg·min-1 1981 
VO2max); HT = High-trained (60+ ml·kg·min-1 VO2max). s = significant change post-exercise (p < 1982 
0.05); ns = non-significant change post-exercise (p >0.05); c = control/placebo trial of study 1983 
 1984 
 1985 
 1986 
 1987 
 1988 
 1989 
71 
Table 4. Influence of acute exercise-(heat) stress on systemic gastrointestinal microbial 1990 
translocation responses 1991 
Reference Subjects Exercise Protocol Peak 
TCore (°C) 
Mean 
HR 
(bpm) 
Endotoxin          
(Δ pre-to-post 
exercise) 
Antunes et al. 
[297] 
19 male 
(MT) 
56 ± 7 minutes cycling at 90% of first 
ventilatory threshold (fasted) in 22.1°C 
(55% RH) 
N/A 141 -3 pg·ml-1                  
(-3%) ns 
Yeh et al.  
(Part B) [138] 
15 male 
and 1 
female 
(LT) 
60 minutes running at 70% VO2max 
(fed) in Tamb 22°C (66% RH) 
38.4  ~145 
 
-1.1 pg·ml-1 
(-10%) ns 
Zuhl et al. 
[116] 
2 male 
and 5 
female 
(LT/MT) 
60 minutes running at 70% VO2max 
(fasted) in Tamb 30°C (12-20% RH) 
39.5 N/A -0.2 pg·ml-1             
(-7%) ns, c 
Osborne et al. 
(Part A) [133] 
8 Male 
(MT-HT) 
30 minutes cycling at 50/70% Wattmax, 
then 30 minutes at 50% wattmax 
(fasted) in Tamb 20°C (55% RH) 
38.5 165 0.1 pg·ml-1 
(1%) ns, # 
Osborne et al. 
(Part B) [133] 
8 Male 
(MT-HT) 
30 minutes cycling at 50/70% Wattmax, 
then 30 minutes at 50% wattmax 
(fasted) in Tamb 35°C (53% RH) 
39.5 182 0.2 pg·ml-1 
(1%) s, # 
Karhu et al. 
[132] 
 
17 males 
(MT-HT) 
90 minutes running at 80% of best 10 
km race time (fed) in Tamb not reported 
N/A  N/A 0.3 pg·ml-1              
(~ 1%) ns, c 
Kuennen et al. 
[143] 
8 male 
(MT) 
100 minutes walking (6.3 km·h-1) at 
50% VO2max (fasted) in Tamb 46.5°C 
(20% RH) 
39.3 N/A ~0.5 pg·ml-1 
(10%) ns, c 
Ng et al. [73] 30 males 
(HT) 
Half-marathon (fed) in Tamb 27°C (84% 
RH) 
40.7 172 0.6 pg·ml-1    
(32%) s 
Jeukendrup et 
al. [144] 
29 male 
and 1 
female 
(HT) 
Ironman (3.8 km swim; 185 km cycle; 
42.2 km run) (fed) in Tamb 9-32°C 
N/A N/A 1.7 pg·ml-1 
(666%) s 
Guy et al. 
[298] 
20 male 
(LT-MT) 
10 minutes cycling at 50%, 60%, and 
70% wattmax, then 5 km (fasted) in Tamb 
35°C (70% RH) 
38.9 160 2 pg·ml-1  
(9%) ns 
Selkirk et al.  
(Part B) [126] 
12 male 
(HT) 
To fatigue (~122 minutes) uphill walk 
at 4.5 km.h-1 (fasted) in Tamb 40°C (30% 
RH) 
39.7 156 ~3 pg·ml-1 
(200%) s 
Shing et al. 
[146] 
10 male 
(HT)  
~33 minutes running to fatigue at 80% 
VE (fed) in Tamb 35°C (40% RH)  
39.4 172 4 pg·ml-1      
(15%) s  
Snipe et al. 
(Part A) [115, 
125] 
6 male 
and 4 
female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 22°C (44% RH) 
38.5 ~150  4.1 pg·ml-1    
(5%) ns 
Yeh et al.   
(Part B) [138] 
15 male 
and 1 
female 
(LT) 
60 minutes running at 70% VO2max 
(fed) in Tamb 33°C (50% RH) 
39.3  ~145 
 
5 pg·ml-1      
(54%) s 
Antunes et al. 
(Part B) [297]  
19 male 
(MT) 
45 ± 18 minutes cycling at midpoint 
between first and second ventilatory 
threshold (fasted) in 22.1°C (55% RH)  
N/A 162 5 pg·ml-1            
(7%) ns 
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Antunes et al. 
(Part C) [297] 
19 male 
(MT) 
10 ± 9 minutes cycling at midpoint 
between second ventilatory threshold 
and maximal aerobic power (fasted) in 
22.1°C (55% RH) 
N/A 180 6 pg·ml-1            
(5%) ns 
Ashton et al. 
[286] 
10 males 
(LT) 
VO2max test (~15 minutes)  on cycle 
ergometer (fasted) in Tamb not 
reported 
N/A N/A 9.4 pg·ml-1   
(72%) s 
Snipe et al. 
(Part B) [115] 
6 male 
and 4 
female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (26% RH) 
39.6 ~170  9.8 pg·ml-1  
(11%) s 
Gill et al. [149] 8 male 
(MT-HT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 32°C (34% RH) 
38.6 165 10 pg·ml-1      
(4%) ns, c 
Snipe et al. 
[193] 
6 male 
and 5 
female 
(MT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (30% RH) 
39.3 159 10 pg·ml-1            
(N/A %) nb 
Selkirk et al.  
(Part A) [126] 
11 male 
(LT-MT) 
To fatigue (~106 minutes) uphill walk 
at 4.5 km.h-1 (fasted) in Tamb 40°C (30% 
RH) 
39.1 164 ~10 pg·ml-1 
(300%) s 
Lim et al. (Part 
B) [150] 
 
9 male 
(HT) 
To fatigue (time not given) at 70% 
VO2max (fed) in Tamb 35°C (40% RH) 
39.5 N/A 13 pg·ml-1     
(92%) s,c 
Guy et al. 
[299] 
8 male 
(LT) 
10 minutes cycling at 50%, 60%, and 
70% wattmax, then 5 km (fasted) in Tamb 
35°C (70% RH) 
38.6 161 16 pg·ml-1  
(9%) ns, c, # 
Gill et al. [71] 13 male 
and 6 
female 
(HT) 
Multistage ultra-marathon stage 1 (37 
km) (fed) in Tamb 32-40°C (32-40% RH) 
N/A N/A 40 pg·ml-1      
(14%) s 
Barberio et al. 
[72] 
9 male 
(MT) 
~24 minutes running at 78% VO2max 
(fed) in Tamb 40°C (40% RH) prior to 
heat acclimation 
39.0 N/A 40 pg·ml-1     
(57%) s,c 
Moss et al. 
[151] 
9 male 
(HT) 
45 minutes cycling at 40% PPO 
(unstated prandial state) in Tamb 40°C 
(50% RH) prior to heat acclimation 
38.9 153 52 pg·ml-1     
(27%) s,c 
Costa et al. 
[135] 
11 male 
(MT-HT) 
120 minutes running at 70% VO2max 
(fed) in Tamb 25°C (35% RH) 
N/A 148 96 pg·ml-1 (46%) 
ns, c, # 
Gill et al. [145] 14 male 
and 3 
female 
(HT) 
24 hour ultramarathon (fed) in Tamb 0-
20°C (54-82% RH) 
N/A N/A 122 pg·ml-1 
(37%) s, # 
Machado et al.  
(Part A) [300] 
9 male 
(MT) 
60 minutes running at 50% VO2max 
(fasted) in Tamb not reported 
N/A N/A 130 pg·ml-1 
(33%) ns, # 
Machado et al.  
(Part B) [300] 
9 male 
(MT) 
60 minutes running at 50% VO2max 
(fasted) in Tamb not reported (FIO2 = 
13.5%) 
N/A N/A 250 pg·ml-1 
(48%) s, # 
Gaskell et al. 
[147] 
10 male 
and 8 
female 
(MT-HT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (25% RH) 
38.6 ~151 LBP ~-2 µg·ml-1   
(N/A%) ns, c 
Selkirk et al.  
(Part A) [146] 
11 male 
(HT) 
To fatigue (~163 minutes) uphill walk 
at 4.5 km.h-1 (fasted) in Tamb 40°C (30% 
RH) 
39.1 164 LBP ~0 µg·ml-1 
(0%) ns 
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Moncada-
Jiminez et al. 
[195] 
 
11 male 
(MT-HT) 
135-minute laboratory duathlon at 
71% VO2max (15km run and 30km 
cycle) (fasted) in Tamb not reported 
38.5 N/A LBP ~0.59 µg·ml-
1 (22%) s, c 
Selkirk et al.  
(Part B) [146] 
12 male 
(LT-MT) 
To fatigue (~106 minutes) uphill walk 
at 4.5 km.h-1 (fasted) in Tamb 40°C (30% 
RH) 
39.7 156 LBP ~1.5 µg·ml-1 
(15%) s 
Jonvik et al. 
[131] 
16 male 
(HT) 
60 minutes cycling at 70% wattmax 
(fasted) in Tamb not reported 
N/A N/A LBP 1.6 µg·ml-1 
(13%) s 
Costa et al. 
[135] 
11 male 
(MT-HT) 
120 minutes running at 70% VO2max 
(fed) in Tamb 25°C (35% RH) 
N/A 148 sCD14-ST 0.05 
µg·ml-1 (N/A%) 
ns,c 
Gaskell et al. 
[147]  
10 male 
and 8 
female 
(MT-HT) 
120 minutes running at 60% VO2max 
(fed) in Tamb 35°C (25% RH) 
38.6 ~151 sCD14-ST 0.1 
µg·ml-1   (N/A%) 
s, c 
Stuempfle et 
al. [301] 
15 male 
and 5 
female 
(MT) 
161-km ultramarathon (26.8 ± 2.4 
hours; fed) in Tamb 0-30°C (N/A RH) 
38.3 N/A sCD14-ST 0.6 
µg·ml-1 (63%) s 
Pugh et al. 
[148] 
10 male 
and 2 
female 
(MT) 
42.4 km track marathon (4.1 ± 0.8 
hours; fed) in Tamb 16-17°C (N/A RH) 
N/A ~160 sCD14-ST 5.4 
µg·ml-1 (164%) s, c 
LT = Low-trained (35-49 ml·kg·min-1 VO2max); MT = Moderate-trained (50-59 ml·kg·min-1 1992 
VO2max); HT = High-trained (60+ ml·kg·min-1 VO2max). s = significant change post-exercise (p < 1993 
0.05); ns = non-significant change post-exercise (p >0.05); nb = no baseline resting data to 1994 
compare with; c = control/placebo trial of study. # Where data have been converted from 1995 
EU·ml-1 to pg·ml-1 through standard conversions (1 EU·ml-1 = 100 pg·ml-1) 1996 
 1997 
 1998 
 1999 
 2000 
 2001 
 2002 
 2003 
 2004 
 2005 
 2006 
 2007 
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Table 5. Evidence basis of nutritional supplements to help protect exercise-induced GI barrier 2008 
integrity loss 2009 
Nutrient Evidence  Dosing Consensus and Limitations 
Carbohydrate Cell:   - -  
Clinical:   + + - 
Exercise:   + + + 
30-108 g·kg·h-1 
liquid multi-
transportable 
CHO.  
Effects of pre- exercise CHO status or 
solid CHO ingestion unknown. 
Greater exploration on CHO timing 
and types required.  
L- Glutamine Cell:   + + + - 
Clinical:   + + -  
Exercise:   + + + 
0.25-0.9 
g·kg·FFM.-1 
given 1-2 hours 
pre-exercise.  
Dose ≥  0.25g·kg·FFM-1 appears 
favourable. High doses poorly 
tolerated in some individuals. No 
evidence during prolonged exercise 
or on MT.  
Bovine 
Colostrum 
Cell:   + + + + 
Clinical:   + + + 
Exercise:   + +   
20 g·day-1 for 14 
days pre-
exercise 
Potentially useful following less 
demanding exercise. No effects with 
short-term supplementation. Certain 
formulations might be more 
beneficial.  
Nitric Oxide Cell:   + +  
Clinical:   + + 
Exercise:   - - 
More evidence 
required  
No benefits of L-citrulline or sodium 
nitrate. Nitrate ingestion might 
compromise thermoregulation with 
exercise in the heat. Only two human 
exercise studies.  
Probiotics Cell:   + - 
Clinical:   + + - - 
Exercise:   + - - 
More evidence 
required 
Contrasting results between 
formulations. Multi-strain probiotics 
seem favourable. Negative responses 
have been reported. Further 
evidence required. 
Polyphenols Cell:   + + - - 
Clinical:   + - 
Exercise:   + - 
3 days of 0.5 
g·day-1 of 
curcumin. 
Quercetin not 
recommended  
Contrasting results between 
formulations. Only two human 
exercise studies. Further evidence 
required. 
Zinc 
Carnosine 
Cell:   + + + 
Clinical:   + + 
Exercise:   +   
75 mg·day-1 for ≥ 
2 days 
Unknown effects in severe exercise 
situations. A 150 mg·day-1 dose 
warrants research. Only one human 
exercise study. Further evidence 
required. 
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